APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 04
April 2006



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2006

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

Cumulative Supplement 04

April 2006

CONTENTS

Note:
Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

26th EDITION

CUMULATIVE SUPPLEMENT 04
April 2006

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AVENTIS PHARMACEUTICALS INC (AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
AVENTIS PHARMACEUTICAL PRODUCTS INC (AVENTIS PHARMS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)

DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
CLAY PARK LABS INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
LOREX PHARMACEUTICALS (LOREX)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
MARTEC SCIENTIFIC INC (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
PRIVATE FORMULATIONS INC (PRIVATE FMLTNS)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
PHARMACEUTICAL FORMULATIONS INC (PHARM FORM)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
SANOFI AVENTIS US INC (SANOFI AVENTIS US)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI-AVENTIS US INC (SANOFI AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI INC (SANOFI)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO RESEARCH DIV SANOFI SYNTHELABO INC (SANOFI SYN RES)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
STERIS LABORATORIES INC (STERIS)	WATSON LABORATORIES INC (WATSON)
UCB PHARMA INC (UCB PHARMA)	UCB INC (UCB INC)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at http://www.fda.gov/cder/ob/default.htm. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2005	MAR 2006	SEP 2006	DEC 2006
DRUG PRODUCTS LISTED	11368	11487		
SINGLE SOURCE	2428	2461		
	(21.4%)	(21.4%)		
MULTISOURCE	8851	8937		
	(77.9%)	(77.8%)		
THERAPEUTICALLY EQUIVALENT	8642	8730		
	(76.04%)	(76.0%)		
NOT THERAPEUTICALLY EQUIVALENT	209	207		
	(1.8%)	(1.8%)		
EXCEPTIONS[1]	89	89		
	(0.8%)	(0.8%)		
NEW MOLECULAR ENTITIES APPROVED	11	6		
NUMBER OF APPLICANTS	628	629		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

		BUTAPAP							
	AB	+ MIKART	650MG;50MG	N89988	001	Oct 26, 1992	Jan		CRLD
		SEDAPAP							
		@ MAYRAND	650MG;50MG	N88944	001	Oct 17, 1985	Jan		DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE							
		@ CLONMEL	120MG/5ML;12MG/5ML	N40098	001	Sep 20, 1996	Jan		DISC

TABLET; ORAL

		ACETAMINOPHEN AND CODEINE PHOSPHATE							
>D>	AA	TEVA	300MG;60MG	N88629	001	Mar 06, 1985	Apr		CRLD
>A>	AA	+	300MG;60MG	N88629	001	Mar 06, 1985	Apr		CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
		@ ENDO PHARMS	500MG;7.5MG	N40280	001	Sep 30, 1998	Feb		DISC
		@	650MG;7.5MG	N40280	002	Sep 30, 1998	Feb		DISC
		@	650MG;10MG	N40280	003	Sep 30, 1998	Feb		DISC
		@	750MG;7.5MG	N40281	002	Sep 30, 1998	Feb		DISC
		MIKART	300MG;5MG	N40658	001	Jan 19, 2006	Jan		NEWA
		+	300MG;7.5MG	N40556	002	Mar 24, 2006	Mar		NEWA
	AA	VINTAGE PHARMS	325MG;5MG	N40655	001	Jan 19, 2006	Jan		NEWA
	AA		325MG;7.5MG	N40656	001	Jan 19, 2006	Jan		NEWA
		HY-PHEN							
		@ ASCHER	500MG;5MG	N87677	001	May 03, 1982	Mar		DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

		OXYCODONE AND ACETAMINOPHEN							
>A>		+ MIKART	400MG;5MG	N40687	001	Apr 27, 2006	Apr		NEWA
>A>		+	400MG;7.5MG	N40698	001	Apr 27, 2006	Apr		NEWA
>A>		+	400MG;10MG	N40692	001	Apr 27, 2006	Apr		NEWA
>A>			500MG;10MG	N40676	001	Apr 19, 2006	Apr		NEWA

ACETAZOLAMIDE

TABLET; ORAL

		ACETAZOLAMIDE							
	AB	+ TARO	250MG	N40195	002	May 28, 1997	Mar		CRLD
		DIAMOX							
		@ DURAMED PHARMS BARR	125MG	N08943	001		Mar		DISC
		@	250MG	N08943	002		Mar		DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

		HYDROCORTISONE AND ACETIC ACID							
	AT	VINTAGE	2%;1%	N40609	001	Feb 06, 2006	Jan		NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

	@ GENPHARM	0.09MG/INH	N73045	001	Aug 19, 1997	Feb	DISC
	@ PLIVA	0.09MG/INH	N74072	001	Aug 01, 1996	Feb	DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN	RXELITE	EQ 0.083% BASE	N77569	001	Apr 04, 2006	Mar	NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;0.03MG/ML	N21163	001	May 18, 2000	Jan	CAHN

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+	SANDOZ	2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;30UGM/ML	N21559	001	Jun 16, 2003	Jan	CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB	MYLAN	0.5MG	N77391	002	Jan 26, 2006	Jan	NEWA
AB		1MG	N77391	003	Jan 26, 2006	Jan	NEWA
AB		2MG	N77391	004	Jan 26, 2006	Jan	NEWA
AB		3MG	N77391	001	Jan 26, 2006	Jan	NEWA

XANAX XR

AB	PHARMACIA AND UPJOHN	0.5MG	N21434	001	Jan 17, 2003	Jan	CFTG
AB		1MG	N21434	002	Jan 17, 2003	Jan	CFTG
AB		2MG	N21434	003	Jan 17, 2003	Jan	CFTG
AB	+	3MG	N21434	004	Jan 17, 2003	Jan	CFTG

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	AMIDE PHARM	100MG	N77659	001	Feb 23, 2006	Feb	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

>A>	NOVARTIS	EQ 5MG BASE;40MG	N20364	007	Apr 11, 2006	Apr	NEWA
>D>	+	EQ 10MG BASE;20MG	N20364	005	Jun 20, 2002	Apr	CRLD
>A>		EQ 10MG BASE;20MG	N20364	005	Jun 20, 2002	Apr	CRLD
>A>	+	EQ 10MG BASE;40MG	N20364	006	Apr 11, 2006	Apr	NEWA

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB	PADDOCK	EQ 12% BASE	N76829	001	Feb 07, 2006	Jan	NEWA

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB	AM ANTIBIOTICS	250MG	N62058	001		Jan	CAHN
AB		500MG	N62058	002		Jan	CAHN

FOR SUSPENSION; ORAL
AMOXICILLIN

AB	AM ANTIBIOTICS	125MG/5ML	N62059	001		Jan	CAHN
AB		250MG/5ML	N62059	002		Jan	CAHN

TABLET; ORAL
AMOXICILLIN

AB	HIKMA	875MG	N65255	001	Mar 29, 2006	Mar	NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL
AMPICILLIN TRIHYDRATE

@	AM ANTIBIOTICS	EQ 250MG BASE	N61602	001		Jan	CAHN
@		EQ 500MG BASE	N61602	002		Jan	CAHN

FOR SUSPENSION; ORAL
AMPICILLIN TRIHYDRATE

@	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61601	001		Jan	CAHN
@		EQ 250MG BASE/5ML	N61601	002		Jan	CAHN

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)
ERAXIS

+	VICURON	50MG/VIAL	N21632	001	Feb 17, 2006	Feb	NEWA

ANISINDIONE

TABLET; ORAL
MIRADON

@	SCHERING	50MG	N10909	003		Jan	DISC

>D> ARTICAINE HYDROCHLORIDE; EPINEPHRINE

>D> INJECTABLE; INJECTION
>D> SEPTOCAINE

>D>	DEPROCO	4%;EQ 0.005MG BASE/ML	N22010	001	Mar 30, 2006	Apr	CAIN
		4%;EQ 0.005MG BASE/ML	N22010	001	Mar 30, 2006	Mar	NEWA
>D>	+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971	001	Apr 03, 2000	Apr	CAIN
	+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971	001	Apr 03, 2000	Mar	CPOT

>A> ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

>A> INJECTABLE; INJECTION
>A> SEPTOCAINE

>A>	+ DEPROCO	4%;EQ 0.0085MG BASE/1.7ML(4%; EQ 0.005MG BASE/ML)	N22010	001	Mar 30, 2006	Apr	CAIN
>A>	+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971	001	Apr 03, 2000	Apr	CAIN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265	001	Feb 21, 2001	Jan	CAHN

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+	SANDOZ	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646	001	Jan 29, 2004	Jan	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@	ENDO PHARMS	325MG;50MG;40MG;30MG	N75351	001	Mar 05, 1999	Feb	DISC	
>A>		FIORINAL W/CODEINE						
>A>	AB	+ WATSON PHARMS	325MG;50MG;40MG;30MG	N19429	003	Oct 26, 1990	Apr	CTNA
>D>		FIORINAL W/CODEINE NO 3						
>D>	AB	+ WATSON PHARMS	325MG;50MG;40MG;30MG	N19429	003	Oct 26, 1990	Apr	CTNA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

PERCODAN-DEMI

@	ENDO PHARMS	325MG;2.25MG;0.19MG	N07337	005		Feb	DISC	

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

@	PFIZER	125MG/5ML	N50556	001	Mar 23, 1982	Feb	DISC	

TABLET; ORAL

SPECTROBID

@	PFIZER	400MG	N50520	001		Feb	DISC	

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB	APOTEX INC	5MG	N77128	001	Mar 08, 2006	Feb	NEWA	
AB		10MG	N77128	002	Mar 08, 2006	Feb	NEWA	
AB		20MG	N77128	003	Mar 08, 2006	Feb	NEWA	
AB		40MG	N77128	004	Mar 08, 2006	Feb	NEWA	
AB	BIOKEY	5MG	N76820	001	Feb 03, 2006	Jan	NEWA	
AB		10MG	N76820	002	Feb 03, 2006	Jan	NEWA	
AB		20MG	N76820	003	Feb 03, 2006	Jan	NEWA	
AB		40MG	N76820	004	Feb 03, 2006	Jan	NEWA	

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

>A>		BENZPHETAMINE HYDROCHLORIDE						
>A>	AA	PADDOCK	50MG	N40578	001	Apr 17, 2006	Apr	NEWA
		DIDREX						
>D>		+ PHARMACIA AND UPJOHN	50MG	N12427	002		Apr	CFTG
>A>	AA	+	50MG	N12427	002		Apr	CFTG

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
EMETE-CON
@ PFIZER EQ 50MG BASE/VIAL N16820 001 Mar DISC

BETAINE, ANHYDROUS

FOR SOLUTION; ORAL
CYSTADANE
\+ JAZZ 1GM/SCOOPFUL N20576 001 Oct 25, 1996 Feb CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL
TACLONEX
\+ LEO PHARM PRODS 0.064%;0.005% N21852 001 Jan 09, 2006 Jan NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
BRIMONIDINE TARTRATE
AT AKORN 0.2% N76439 001 Mar 14, 2006 Feb NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
AZOPT
\+ ALCON 1% N20816 001 Apr 01, 1998 Feb CAHN

BUDESONIDE

SPRAY, METERED; NASAL
RHINOCORT
\+ ASTRAZENECA 0.032MG/INH N20746 001 Oct 01, 1999 Mar CRLD
@ 0.064MG/INH N20746 002 Oct 01, 1999 Mar DISC

BUMETANIDE

INJECTABLE; INJECTION
BUMETANIDE
AP \+ BEDFORD 0.25MG/ML N74441 001 Jan 27, 1995 Feb CRLD
BUMEX
@ ROCHE 0.25MG/ML N18226 001 Feb 28, 1983 Feb DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE
>A> \+ HOSPIRA 0.5% N22046 002 Jul 13, 1983 Apr NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE
>A> \+ HOSPIRA 0.5%;EQ 0.009MG BASE/ML N22046 001 Jul 13, 1983 Apr NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HYDROCHLORIDE
AB APOTEX INC 75MG N76143 001 Jan 17, 2006 Jan NEWA
AB 100MG N76143 002 Jan 17, 2006 Jan NEWA

BUSULFAN

INJECTABLE; INJECTION

	BUSULFEX							
+	PDL BIOPHARMA INC	6MG/ML	N20954	001	Feb 04, 1999	Jan	CAHN	

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

	CAFERGOT							
@	NOVARTIS	100MG;2MG	N09000	002		Feb	DISC	
	MIGERGOT							
+	G AND W LABS	100MG;2MG	N86557	001	Oct 04, 1983	Feb	CRLD	

CALCIPOTRIENE

CREAM; TOPICAL

	DOVONEX							
+	LEO PHARM	0.005%	N20554	001	Jul 22, 1996	Feb	CAHN	

OINTMENT; TOPICAL

	DOVONEX							
+	LEO PHARM	0.005%	N20273	001	Dec 29, 1993	Feb	CAHN	

SOLUTION; TOPICAL

	DOVONEX							
+	LEO PHARM	0.005%	N20611	001	Mar 03, 1997	Feb	CAHN	

CALCITONIN, SALMON

INJECTABLE; INJECTION

	MIACALCIN							
+	NOVARTIS	200 IU/ML	N17808	002	Mar 29, 1991	Jan	CTEC	

CALCITRIOL

CAPSULE; ORAL

	CALCITRIOL							
AB	ROXANE	0.25UGM	N76917	001	Mar 27, 2006	Mar	NEWA	

INJECTABLE; INJECTION

	CALCITRIOL							
AP	GENIX THERAP	0.001MG/ML	N77102	001	Feb 08, 2006	Jan	NEWA	

CAPTOPRIL

TABLET; ORAL

	CAPTOPRIL							
@	CLONMEL HLTHCARE	12.5MG	N74423	001	Feb 13, 1996	Jan	DISC	
@		25MG	N74423	002	Feb 13, 1996	Jan	DISC	
@		50MG	N74423	003	Feb 13, 1996	Jan	DISC	
@		100MG	N74423	004	Feb 13, 1996	Jan	DISC	
@	ENDO LABS	12.5MG	N74418	001	Feb 13, 1996	Feb	DISC	
@		25MG	N74418	002	Feb 13, 1996	Feb	DISC	
@		50MG	N74418	003	Feb 13, 1996	Feb	DISC	
@		100MG	N74418	004	Feb 13, 1996	Feb	DISC	

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
@	ENDO LABS	25MG;15MG	N74788	001	Dec 29, 1997	Feb	DISC	
@		25MG;25MG	N74788	002	Dec 29, 1997	Feb	DISC	
@		50MG;15MG	N74788	004	Dec 29, 1997	Feb	DISC	

TABLET; ORAL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	@	ENDO LABS	50MG;25MG	N74788	003	Dec 29, 1997	Feb	DISC

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

AP		WATSON LABS	50MG/VIAL	N77383	001	Jan 27, 2006	Jan	NEWA
AP			150MG/VIAL	N77383	002	Jan 27, 2006	Jan	NEWA
AP			450MG/VIAL	N77383	003	Jan 27, 2006	Jan	NEWA

INJECTABLE; IV (INFUSION)
CARBOPLATIN

	@	AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247	001	Oct 21, 2004	Feb	DISC
AP			EQ 50MG/5ML (10MG/ML)	N77266	001	Feb 15, 2006	Jan	NEWA
	@		EQ 150MG/15ML (10MG/ML)	N77247	002	Oct 21, 2004	Feb	DISC
AP			EQ 150MG/15ML (10MG/ML)	N77266	002	Feb 15, 2006	Jan	NEWA
AP			EQ 450MG/45ML (10MG/ML)	N77266	003	Feb 15, 2006	Jan	NEWA
AP			EQ 600MG/60ML (10MG/ML)	N77266	004	Feb 15, 2006	Jan	NEWA
AP		BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244	004	Jan 20, 2006	Jan	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

AB	+	IVAX PHARMS	EQ 500MG BASE	N62766	001	Mar 03, 1987	Mar	CRLD
AB		TEVA PHARMS	EQ 500MG BASE	N65282	001	Jan 20, 2006	Jan	NEWA
AB		WESTWARD	EQ 500MG BASE	N65311	001	Feb 07, 2006	Jan	NEWA

DURICEF

	@	WARNER CHILCOTT	EQ 500MG BASE	N50512	001		Jan	DISC

FOR SUSPENSION; ORAL
CEFADROXIL

		RANBAXY	EQ 125MG BASE/5ML	N65115	001	Mar 26, 2003	Feb	CTEC
AB		TEVA PHARMS	EQ 250MG BASE/5ML	N65278	001	Jan 20, 2006	Jan	NEWA
AB			EQ 500MG BASE/5ML	N65278	002	Jan 20, 2006	Jan	NEWA

DURICEF

	@	WARNER CHILCOTT	EQ 125MG BASE/5ML	N50527	002		Feb	DISC

TABLET; ORAL
CEFADROXIL

AB		HIKMA	EQ 1GM BASE	N65260	001	Mar 30, 2006	Mar	NEWA
AB	+	IVAX PHARMS	EQ 1GM BASE	N62774	001	Apr 08, 1987	Feb	CRLD

DURICEF

	@	WARNER CHILCOTT	EQ 1GM BASE	N50528	001		Jan	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP		ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313	001	Jan 23, 2006	Jan	NEWA
AP			EQ 2GM BASE/VIAL	N65313	002	Jan 23, 2006	Jan	NEWA
AP			EQ 10GM BASE/VIAL	N65312	001	Feb 13, 2006	Jan	NEWA

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP		B BRAUN	EQ 1GM BASE/VIAL	N65214	001	Mar 10, 2006	Feb	NEWA
AP			EQ 2GM BASE/VIAL	N65214	002	Mar 10, 2006	Feb	NEWA

CEFTRIAXONE

INJECTABLE; INJECTION
CEFTRIAXONE

>A>	AP	TEVA	EQ 10GM BASE/VIAL	N65274	001	May 01, 2006	Apr	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

	AP	AM PHARM PARTNERS	EQ 250MG BASE/VIAL	N65245	001	Feb 15, 2006	Jan	NEWA
	AP		EQ 500MG BASE/VIAL	N65245	002	Feb 15, 2006	Jan	NEWA
	AP		EQ 1GM BASE/VIAL	N65245	003	Feb 15, 2006	Jan	NEWA
	AP		EQ 2GM BASE/VIAL	N65245	004	Feb 15, 2006	Jan	NEWA

INJECTABLE; INJECTION
CEFTRIAXONE

	AP	AM PHARM	EQ 10GM BASE/VIAL	N65252	001	Feb 15, 2006	Jan	NEWA

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

	AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	N65308	001	Mar 29, 2006	Mar	NEWA
	AB		EQ 250MG BASE	N65308	002	Mar 29, 2006	Mar	NEWA
	AB		EQ 500MG BASE	N65308	003	Mar 29, 2006	Mar	NEWA

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

	AB	HIKMA	EQ 250MG BASE	N65215	001	Jan 24, 2006	Jan	NEWA
	AB		EQ 500MG BASE	N65215	002	Jan 24, 2006	Jan	NEWA

CEPHRADINE

CAPSULE; ORAL
ANSPOR

		@ GLAXOSMITHKLINE	250MG	N61859	001		Mar	DISC
		@	500MG	N61859	002		Mar	DISC

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX

	AB	PERRIGO	0.77%	N77364	001	Mar 03, 2006	Mar	CAHN
	AB	PERRIGO NEW YORK	0.77%	N77364	001	Mar 03, 2006	Feb	NEWA

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL

	AB	MUTUAL PHARM	50MG	N77208	002	Mar 29, 2006	Mar	NEWA
	AB		100MG	N77208	001	Mar 29, 2006	Mar	NEWA
>A>	AB	MYLAN	50MG	N77323	002	Apr 20, 2006	Apr	NEWA
>A>	AB		100MG	N77323	001	Apr 20, 2006	Apr	NEWA

CIMETIDINE

TABLET; ORAL
CIMETIDINE

		@ ENDO PHARMS	200MG	N74281	001	May 17, 1994	Feb	DISC
		@	300MG	N74281	002	May 17, 1994	Feb	DISC

TABLET; ORAL
CIMETIDINE
@ ENDO PHARMS 400MG N74281 003 May 17, 1994 Feb DISC
@ 800MG N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HYDROCHLORIDE
@ ENDO PHARMS EQ 300MG BASE/2ML N74005 001 Aug 31, 1994 Feb DISC

SOLUTION; ORAL
CIMETIDINE HYDROCHLORIDE
@ ENDO PHARMS EQ 300MG BASE/5ML N74251 001 Dec 22, 1994 Feb DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE
AB TARO EQ 10MG BASE N77278 001 Mar 22, 2006 Mar NEWA
AB EQ 20MG BASE N77278 002 Mar 22, 2006 Mar NEWA
AB EQ 40MG BASE N77278 003 Mar 22, 2006 Mar NEWA
AB TEVA PHARMS EQ 10MG BASE N77213 001 Mar 31, 2006 Mar NEWA
AB EQ 20MG BASE N77213 002 Mar 31, 2006 Mar NEWA
AB EQ 40MG BASE N77213 003 Mar 31, 2006 Mar NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL
CLARITHROMYCIN
>D> RANBAXY 1GM N65210 001 Jan 26, 2005 Apr CRLD
>A> + 1GM N65210 001 Jan 26, 2005 Apr CRLD

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE
AT ALTANA EQ 1% BASE N65254 001 Feb 14, 2006 Jan NEWA

CLOBETASOL PROPIONATE

SPRAY; TOPICAL
CLOBEX
+ GALDERMA LABS LP 0.05% N21835 001 Oct 27, 2005 Feb CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL
CLOPIDOGREL BISULFATE
AB APOTEX EQ 75MG BASE N76274 001 Jan 20, 2006 Jan NEWA
PLAVIX
AB + SANOFI SYNTHELABO EQ 75MG BASE N20839 001 Nov 17, 1997 Jan CFTG

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETH VC W/ CODEINE
+ ALPHARMA US PHARMS 10MG/5ML;5MG/5ML;6.25MG/5ML N88764 001 Oct 31, 1984 Jan CTEC
PROMETHAZINE VC W/ CODEINE
@ MORTON GROVE 10MG/5ML;5MG/5ML;6.25MG/5ML N88896 001 Jan 04, 1985 Jan DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE WITH CODEINE SYRUP

	AA		VINTAGE	10MG/5ML;6.25MG/5ML	N40650	001	Jan 31, 2006	Jan	NEWA

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL
COLESTID

>D>		+	PHARMACIA AND UPJOHN	5GM/PACKET	N17563	004	Sep 22, 1995	Apr	CFTG
>D>				5GM/SCOOPFUL	N17563	003	Sep 22, 1995	Apr	CFTG
>A>	AB			5GM/SCOOPFUL	N17563	003	Sep 22, 1995	Apr	CFTG
>A>	AB	+		5GM/PACKET	N17563	004	Sep 22, 1995	Apr	CFTG

COLESTIPOL HYDROCHLORIDE

>A>	AB		IMPAX LABS	5GM/SCOOPFUL	N77277	001	May 02, 2006	Apr	NEWA
>A>	AB			5GM/PACKET	N77277	002	May 02, 2006	Apr	NEWA

FLAVORED COLESTID

>D>		+	PHARMACIA AND UPJOHN	5GM/PACKET	N17563	001		Apr	CRLD
>A>				5GM/PACKET	N17563	001		Apr	CRLD

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL
GASTROCROM

		+	AZUR PHARMA	100MG/5ML	N20479	001	Feb 29, 1996	Feb	CAHN

CYANOCOBALAMIN

GEL, METERED; NASAL
NASCOBAL

		@	QOL MEDCL	0.5MG/INH	N19722	001	Nov 05, 1996	Mar	DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCL0BENZAPRINE HYDROCHLORIDE

>A>	AB		JUBILANT PHARMS	5MG	N77563	001	Apr 19, 2006	Apr	NEWA
>A>	AB			10MG	N77563	002	Apr 19, 2006	Apr	NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

	AB		AMIDE PHARM	5MG	N77291	001	Feb 03, 2006	Jan	NEWA
	AB		MUTUAL PHARM	5MG	N73541	002	Apr 06, 2006	Mar	NEWA
	AB		MYLAN	5MG	N73144	002	Feb 03, 2006	Jan	NEWA
	AB		SANDOZ	5MG	N72854	002	Feb 03, 2006	Jan	NEWA
	AB		WATSON LABS	5MG	N71611	002	Feb 03, 2006	Jan	NEWA
				7.5MG	N71611	003	Feb 03, 2006	Jan	NEWA

FLEXERIL

	AB		MCNEIL CONS SPECLT	5MG	N17821	001		Jan	CFTG

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION
DEFEROXAMINE MESYLATE

	AP		SICOR PHARMS	500MG/VIAL	N76806	001	Mar 31, 2006	Mar	NEWA
	AP			2GM/VIAL	N76806	002	Mar 31, 2006	Mar	NEWA

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DECLOMYCIN

		@	GLADES PHARMS LLC	75MG	N50261	001		Mar	CAHN

TABLET; ORAL
DECLOMYCIN

AB		GLADES PHARMS LLC	150MG	N50261	002		Mar	CAHN
AB	+		300MG	N50261	003		Mar	CAHN
		@ PROTEIN DESIGN LABS	75MG	N50261	001		Feb	CAHN
AB			150MG	N50261	002		Feb	CAHN
AB	+		300MG	N50261	003		Feb	CAHN

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX-D 12 HOUR

	+	SCHERING	2.5MG;120MG	N21313	001	Feb 01, 2006	Feb	NEWA

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

		@ BEDFORD	0.004MG/ML	N74575	001	Feb 18, 2000	Jan	DISC

DESMOPRESSIN ACETATE PRESERVATIVE FREE

		@ BEDFORD	0.004MG/ML	N74574	001	Feb 18, 2000	Jan	DISC

TABLET; ORAL
DESMOPRESSIN ACETATE

AB		APOTEX	0.1MG	N77414	001	Mar 07, 2006	Feb	NEWA
AB			0.2MG	N77414	002	Mar 07, 2006	Feb	NEWA
AB		TEVA PHARMS	0.1MG	N77122	001	Jan 25, 2006	Jan	NEWA
AB			0.2MG	N77122	002	Jan 25, 2006	Jan	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE

AB	+	DURAMED	0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN
AB	+		0.15MG,N/A;0.02MG,0.01MG	N20713	001	Apr 22, 1998	Feb	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE

AP		BAXTER HLTHCARE	EQ 10MG PHOSPHATE/ML	N87702	001	Sep 07, 1982	Mar	CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

		@ ENDO PHARMS	5MG	N40299	001	May 13, 1999	Feb	DISC

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE DM

AA		VINTAGE	15MG/5ML;6.25MG/5ML	N40649	001	Feb 14, 2006	Jan	NEWA

DIAZEPAM

TABLET; ORAL
DIAZEPAM

AB		VINTAGE PHARMS	2MG	N77749	001	Mar 31, 2006	Mar	NEWA
AB			5MG	N77749	002	Mar 31, 2006	Mar	NEWA
AB			10MG	N77749	003	Mar 31, 2006	Mar	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

		DIFLORASONE DIACETATE						
BX	+	ALTANA	0.05%	N76263	001	Dec 20, 2002	Jan	CRLD
		FLORONE						
		@ PHARMACIA AND UPJOHN	0.05%	N17741	001		Jan	DISC
		FLORONE E						
		@ PHARMACIA AND UPJOHN	0.05%	N19259	001	Aug 28, 1985	Jan	DISC

OINTMENT; TOPICAL

		DIFLORASONE DIACETATE						
AB	+	TARO	0.05%	N75331	001	May 14, 1999	Jan	CRLD
		FLORONE						
		@ PHARMACIA AND UPJOHN	0.05%	N17994	001		Jan	DISC
		PSORCON						
		@ PHARMACIA AND UPJOHN	0.05%	N19260	001	Aug 28, 1985	Jan	DISC

DIGOXIN

INJECTABLE; INJECTION

		DIGOXIN						
AP		SANDOZ	0.25MG/ML	N40481	001	Aug 21, 2003	Jan	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

		DILTZAC						
AB4		APOTEX INC	120MG	N76395	001	Feb 01, 2006	Jan	NEWA
AB4			180MG	N76395	002	Feb 01, 2006	Jan	NEWA
AB4			240MG	N76395	003	Feb 01, 2006	Jan	NEWA
AB4			300MG	N76395	004	Feb 01, 2006	Jan	NEWA
AB4			360MG	N76395	005	Feb 01, 2006	Jan	NEWA

DIPYRIDAMOLE

TABLET; ORAL

		DIPYRIDAMOLE						
>A>	AB	AMIDE PHARM	25MG	N40542	001	Apr 21, 2006	Apr	NEWA
>A>	AB		50MG	N40542	002	Apr 21, 2006	Apr	NEWA
>A>	AB		75MG	N40542	003	Apr 21, 2006	Apr	NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

		DISOPYRAMIDE PHOSPHATE						
		@ IVAX PHARMS	EQ 100MG BASE	N70186	001	Nov 18, 1985	Jan	DISC
		@	EQ 150MG BASE	N70187	001	Nov 18, 1985	Jan	DISC
		@ SANDOZ	EQ 100MG BASE	N70470	001	Dec 10, 1985	Jan	DISC
		@	EQ 150MG BASE	N70471	001	Dec 10, 1985	Jan	DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION

		ANZEMET						
	+	SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624	002	Sep 11, 1997	Mar	CAIN
	+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624	001	Sep 11, 1997	Mar	CAIN
	+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624	003	Dec 11, 2001	Mar	CAIN

TABLET; ORAL
ANZEMET
SANOFI AVENTIS US EQ 50MG BASE N20623 001 Sep 11, 1997 Mar CAIN
\+ EQ 100MG BASE N20623 002 Sep 11, 1997 Mar CAIN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOPAMINE HYDROCHLORIDE
>D> AP + HOSPIRA 40MG/ML N74403 001 May 23, 1996 Apr DISC
>A> @ 40MG/ML N74403 001 May 23, 1996 Apr DISC
>D> AP + INTL MEDICATION 40MG/ML N18014 001 Apr DISC
>A> @ 40MG/ML N18014 001 Apr DISC
>D> AP + SICOR PHARMS 40MG/ML N72999 001 Oct 23, 1991 Apr DISC
>A> @ 40MG/ML N72999 001 Oct 23, 1991 Apr DISC
>D> AP + 80MG/ML N73000 001 Oct 23, 1991 Apr DISC
>A> @ 80MG/ML N73000 001 Oct 23, 1991 Apr DISC

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE
@ PAR PHARM EQ 75MG BASE N65055 004 Apr 18, 2005 Mar DISC
@ EQ 150MG BASE N65055 003 Jul 15, 2005 Mar DISC
RANBAXY EQ 75MG BASE N65053 003 Sep 10, 2003 Mar CTEC
TABLET; ORAL
DOXYCYCLINE
PAR PHARM EQ 75MG BASE N65070 003 Dec 30, 2002 Mar CMFD

DOXYCYCLINE HYCLATE

CAPSULE, DELAYED RELEASE; ORAL
DORYX
>D> AB FH FAULDING CO LTD EQ 75MG BASE N50582 002 Aug 13, 2001 Apr DISC
>A> @ EQ 75MG BASE N50582 002 Aug 13, 2001 Apr DISC
>D> AB + EQ 100MG BASE N50582 001 Jul 22, 1985 Apr DISC
>A> @ EQ 100MG BASE N50582 001 Jul 22, 1985 Apr DISC
>D> AB WARNER CHILCOTT EQ 100MG BASE N62653 001 Oct 30, 1985 Apr DISC
>A> @ EQ 100MG BASE N62653 001 Oct 30, 1985 Apr DISC
DOXYCYCLINE HYCLATE
>D> AB SANDOZ EQ 75MG BASE N65281 001 Dec 21, 2005 Apr CTEC
>A> EQ 75MG BASE N65281 001 Dec 21, 2005 Apr CTEC
>D> AB EQ 100MG BASE N65281 002 Dec 21, 2005 Apr CRLD
>A> + EQ 100MG BASE N65281 002 Dec 21, 2005 Apr CRLD
TABLET; ORAL
DOXYCYCLINE HYCLATE
AB PAR PHARM EQ 20MG BASE N65287 001 Feb 28, 2006 Feb NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
YAZ
\+ BERLEX LABS 3MG;0.02MG N21676 001 Mar 16, 2006 Mar NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
XYLOCAINE W/ EPINEPHRINE
\+ DENTSPLY PHARM 0.02MG/ML;2% N21381 002 Mar CRLD

ERYTHROMYCIN

SOLUTION; TOPICAL
A/T/S

	AT	TARO PHARMS NORTH	2%	N62405	001	Nov 18, 1982	Feb	CAHN

ESTAZOLAM

TABLET; ORAL
ESTAZOLAM

>D>	AB	IVAX PHARMS	1MG	N74826	001	Jul 03, 1997	Apr	CAHN
>D>	AB		2MG	N74826	002	Jul 03, 1997	Apr	CAHN
>A>	AB	PAR PHARM	1MG	N74826	001	Jul 03, 1997	Apr	CAHN
>A>	AB		2MG	N74826	002	Jul 03, 1997	Apr	CAHN

ESTRADIOL

GEL; TOPICAL
ESTROGEL

		@ ASCEND	0.06%	N21166	001	Feb 09, 2004	Jan	CAHN

GEL, METERED; TOPICAL
ESTROGEL

	+	ASCEND	0.06%	N21166	002	Feb 09, 2004	Jan	CAHN

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL
ESTRASORB

	+	ESPRIT PHARMA	0.25%	N21371	001	Oct 09, 2003	Feb	CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL
ENJUVIA

		DURAMED	0.3MG	N21443	001	Dec 20, 2004	Mar	CMFD
			0.45MG	N21443	002	Dec 20, 2004	Mar	CMFD
			0.625MG	N21443	003	May 10, 2004	Mar	CMFD
	+		1.25MG	N21443	004	May 10, 2004	Mar	CMFD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
BALZIVA-21

		BARR	0.035MG;0.4MG	N76198	001	Apr 22, 2004	Mar	CRLD

TABLET; ORAL-28
OVCON-35

	AB	+ WARNER CHILCOTT	0.035MG;0.4MG	N17716	001		Mar	CRLD

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
LOESTRIN 24 FE

	+	WARNER CHILCOTT	0.02MG;1MG	N21871	001	Feb 17, 2006	Feb	NEWA

ETODOLAC

CAPSULE; ORAL
ETODOLAC

		@ ENDO PHARMS	200MG	N74842	001	Jul 17, 1997	Feb	DISC
		@	300MG	N74842	002	Jul 17, 1997	Feb	DISC
	AB	+ TARO	300MG	N75078	002	Apr 30, 1998	Mar	CRLD

CAPSULE; ORAL
LODINE
@ WYETH PHARMS INC 300MG N18922 003 Jan 31, 1991 Mar DISC

TABLET; ORAL
ETODOLAC
@ ENDO PHARMS 400MG N74841 001 Jun 27, 1997 Feb DISC

FENOFIBRATE

CAPSULE; ORAL
LIPOFEN
CIPHER 50MG N21612 001 Jan 11, 2006 Jan NEWA
100MG N21612 002 Jan 11, 2006 Jan NEWA
+ 150MG N21612 003 Jan 11, 2006 Jan NEWA

TABLET; ORAL
FENOFIBRATE
AB + TEVA 160MG N76433 002 May 13, 2005 Jan CRLD
TRICOR
@ ABBOTT 54MG N21203 001 Sep 04, 2001 Jan DISC
@ 160MG N21203 003 Sep 04, 2001 Jan DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
FENOLDOPAM MESYLATE
AP SANDOZ EQ 10MG BASE/ML N77155 001 Feb 15, 2005 Jan CAHN

FENOPROFEN CALCIUM

TABLET; ORAL
FENOPROFEN CALCIUM
@ CLONMEL HLTHCARE EQ 600MG BASE N72326 001 Aug 17, 1988 Jan DISC

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL
ACTIQ (SUGAR-FREE)
CEPHALON EQ 0.2MG BASE N20747 001 Nov 04, 1998 Mar CTNA
+ EQ 0.4MG BASE N20747 002 Nov 04, 1998 Mar CTNA
EQ 0.6MG BASE N20747 003 Nov 04, 1998 Mar CTNA
EQ 0.8MG BASE N20747 004 Nov 04, 1998 Mar CTNA
EQ 1.2MG BASE N20747 005 Nov 04, 1998 Mar CTNA
EQ 1.6MG BASE N20747 006 Nov 04, 1998 Mar CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
FEXOFENADINE HYDROCHLORIDE
AB DR REDDYS LABS LTD 30MG N76502 001 Apr 11, 2006 Mar NEWA
AB 60MG N76502 002 Apr 11, 2006 Mar NEWA
AB 180MG N76502 003 Apr 11, 2006 Mar NEWA

FLUCONAZOLE

TABLET; ORAL
FLUCONAZOLE
AB GLENMARK PHARMA 50MG N77253 001 Jan 25, 2006 Jan NEWA
AB 100MG N77253 002 Jan 25, 2006 Jan NEWA
AB 150MG N77253 003 Jan 25, 2006 Jan NEWA
AB 200MG N77253 004 Jan 25, 2006 Jan NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP		SANDOZ	0.5MG/5ML (0.1MG/ML)	N77071	001	May 03, 2005	Jan	CAHN
AP			1MG/10ML (0.1MG/ML)	N77071	002	May 03, 2005	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

	+	FOREST LABS	EQ 78UGM BASE/INH	N21247	001	Jan 27, 2006	Jan	NEWA

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCITE

	+	ALCON RES	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N21980	001	Mar 28, 2006	Mar	NEWA

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

AP	+	SICOR PHARMS	50MG/ML	N40023	001	Oct 18, 1991	Mar	CRLD

FLUOROURACIL

AP	+	AM PHARM PARTNERS	50MG/ML	N40278	001	Sep 30, 1998	Mar	CRLD
AP	+		50MG/ML	N40279	001	Sep 30, 1998	Mar	CRLD
AP	+		50MG/ML	N40291	001	Mar 24, 1999	Mar	CRLD
AP	+		50MG/ML	N40379	001	Nov 15, 2000	Mar	CRLD
>D> AP	+	BEDFORD	50MG/ML	N89508	001	Jan 26, 1988	Apr	DISC
>A>	@		50MG/ML	N89508	001	Jan 26, 1988	Apr	DISC
AP	+		50MG/ML	N89508	001	Jan 26, 1988	Mar	CRLD
AP	+	SICOR PHARMS	50MG/ML	N40333	001	Jan 27, 2000	Mar	CRLD
AP	+		50MG/ML	N40334	001	Feb 25, 2000	Mar	CRLD
>D> AP	+	STERIS	50MG/ML	N87792	001	Oct 13, 1982	Apr	DISC
AP	+		50MG/ML	N87792	001	Oct 13, 1982	Mar	CRLD
>A>	@	WATSON LABS	50MG/ML	N87792	001	Oct 13, 1982	Apr	DISC

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

>D> AA		PHARM ASSOC	2.5MG/5ML	N40146	001	Aug 21, 1996	Apr	CRLD
>A>	+		2.5MG/5ML	N40146	001	Aug 21, 1996	Apr	CRLD
>D> AA		TEVA PHARMS	2.5MG/5ML	N81310	001	Apr 29, 1993	Apr	DISC
>A>	@		2.5MG/5ML	N81310	001	Apr 29, 1993	Apr	DISC
>D>		PROLIXIN						
>D> AA	+	APOTHECON	2.5MG/5ML	N12145	003		Apr	DISC
>A>	@		2.5MG/5ML	N12145	003		Apr	DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

>A> AB		PAR PHARM	125MG	N75298	001	Sep 18, 2001	Apr	CAHN
>D> AB		TEVA	125MG	N75298	001	Sep 18, 2001	Apr	CAHN

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB		G AND W LABS	0.005%	N77168	001	Mar 03, 2006	Feb	NEWA

SPRAY, METERED; NASAL

FLONASE

AB	+	GLAXOSMITHKLINE	0.05MG/SPRAY	N20121	001	Oct 19, 1994	Feb	CFTG

FLUTICASONE PROPIONATE

AB		ROXANE	0.05MG/SPRAY	N76504	001	Feb 22, 2006	Feb	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB		CARACO	25MG	N75900	001	Feb 23, 2006	Feb	NEWA
AB			50MG	N75900	002	Feb 23, 2006	Feb	NEWA
AB			100MG	N75900	003	Feb 23, 2006	Feb	NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM

AP		HOSPIRA	2.4GM/100ML	N77174	001	May 31, 2005	Feb	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		SANDOZ	100MG	N75428	001	Jan 24, 2006	Jan	NEWA
AB			300MG	N75428	002	Jan 24, 2006	Jan	NEWA
AB			400MG	N75428	003	Jan 24, 2006	Jan	NEWA

TABLET; ORAL

GABAPENTIN

AB		SANDOZ	600MG	N76120	001	Jan 27, 2006	Jan	NEWA
AB			800MG	N76120	002	Jan 27, 2006	Jan	NEWA

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

	+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937	001	Dec 08, 1999	Jan	CPOT
	+		3309MG/10ML (330.9MG/ML)	N20937	002	Dec 08, 1999	Jan	NEWA
	+		4963.5MG/15ML (330.9MG/ML)	N20937	003	Dec 08, 1999	Jan	NEWA
	+		6618MG/20ML (330.9MG/ML)	N20937	004	Dec 08, 1999	Jan	NEWA
	+		16.545GM/50ML (330.9MG/ML)	N20975	001	Dec 08, 1999	Jan	CPOT

OPTIMARK IN PLASTIC CONTAINER

	+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976	001	Dec 08, 1999	Jan	CPOT
	+		3309MG/10ML (330.9MG/ML)	N20976	002	Dec 08, 1999	Jan	NEWA
	+		4963.5MG/15ML (330.9MG/ML)	N20976	003	Dec 08, 1999	Jan	NEWA
	+		6618MG/20ML (330.9MG/ML)	N20976	004	Dec 08, 1999	Jan	NEWA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB		COBALT	1MG	N77280	001	Feb 03, 2006	Jan	NEWA
AB			2MG	N77280	002	Feb 03, 2006	Jan	NEWA
AB			4MG	N77280	003	Feb 03, 2006	Jan	NEWA
AB		GENPHARM	1MG	N77486	001	Feb 10, 2006	Jan	NEWA

TABLET; ORAL
GLIMEPIRIDE

AB		GENPHARM	2MG	N77486	002	Feb 10, 2006	Jan	NEWA
AB			4MG	N77486	003	Feb 10, 2006	Jan	NEWA

GLIPIZIDE

TABLET; ORAL
GLIPIZIDE

		@ ENDO PHARMS	5MG	N74378	001	Nov 28, 1994	Feb	DISC
		@	10MG	N74378	002	Nov 28, 1994	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL
GLIPIZIDE

AB		WATSON LABS	2.5MG	N76467	003	Mar 27, 2006	Mar	NEWA

GLUCOTROL XL

AB		PFIZER	2.5MG	N20329	003	Aug 10, 1999	Mar	CFTG

GLYBURIDE

TABLET; ORAL
DIABETA

BX	+	SANOFI AVENTIS US	5MG	N17532	003	May 01, 1984	Feb	CRLD

HALOBETASOL PROPIONATE

CREAM; TOPICAL
HALOBETASOL PROPIONATE

>D>	AB	AGIS INDS	0.05%	N77123	001	Dec 16, 2004	Apr	CAHN
>A>	AB	PERRIGO ISRAEL	0.05%	N77123	001	Dec 16, 2004	Apr	CAHN

OINTMENT; TOPICAL
HALOBETASOL PROPIONATE

AB		PERRIGO	0.05%	N76872	001	Dec 16, 2004	Mar	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO		SANDOZ	EQ 50MG BASE/ML	N76463	001	Jun 24, 2005	Jan	CAHN
AO			EQ 100MG BASE/ML	N76463	002	Jun 24, 2005	Jan	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP		SANDOZ	EQ 5MG BASE/ML	N76464	001	Sep 29, 2004	Jan	CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
APRESOLINE

		@ NOVARTIS	10MG	N08303	004		Feb	DISC
		@	25MG	N08303	001		Feb	DISC
		@	50MG	N08303	002		Feb	DISC
		@	100MG	N08303	005		Feb	DISC

HYDRALAZINE HYDROCHLORIDE

AA	+	PLIVA	10MG	N89097	001	Dec 18, 1985	Feb	CRLD
AA	+		25MG	N88467	001	May 01, 1984	Feb	CRLD
AA	+		50MG	N88468	001	May 01, 1984	Feb	CRLD
AA	+		100MG	N89098	001	Dec 18, 1985	Feb	CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO	12.5MG;10MG	N77606	001	Mar 14, 2006	Feb	NEWA
AB		12.5MG;20MG	N77606	002	Mar 14, 2006	Feb	NEWA
AB		25MG;20MG	N77606	003	Mar 14, 2006	Feb	NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL
DIOVAN HCT

>A>	NOVARTIS	12.5MG;320MG	N20818	004	Apr 28, 2006	Apr	NEWA
>D>	+	25MG;160MG	N20818	003	Jan 17, 2002	Apr	CRLD
>A>		25MG;160MG	N20818	003	Jan 17, 2002	Apr	CRLD
>A>	+	25MG;320MG	N20818	005	Apr 28, 2006	Apr	NEWA

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N40666	001	Apr 06, 2006	Mar	NEWA

HYDROCORTISONE; NEOMYCIN; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>A>	AT	PHARMAFORCE	1%;EQ 3.5MG BASE;10,000 UNITS	N65219	001	May 01, 2006	Apr	NEWA

HYDROXYZINE PAMOATE

CAPSULE; ORAL
HYDROXYZINE PAMOATE

	BARR	EQ 100MG HCL	N88488	001	Jun 15, 1984	Mar	CTEC

VISTARIL

	@ PFIZER	EQ 100MG HCL	N11459	006		Mar	DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS
BONIVA

	+ ROCHE	EQ 3MG BASE/3ML	N21858	001	Jan 06, 2006	Jan	NEWA

IBUPROFEN LYSINE

>A>	INJECTABLE; INTRAVENOUS							
>A>	NEOPROFEN							
>A>	+ FARMACON IL	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N21903	001	Apr 13, 2006	Apr	NEWA

INDOMETHACIN

SUPPOSITORY; RECTAL

>A>	INDOMETHACIN							
>A>	+ G AND W LABS	50MG	N73314	001	Aug 31, 1992	Apr	CTNA
>D>	INDOMETHEGAN							
>D>	+ G AND W LABS	50MG	N73314	001	Aug 31, 1992	Apr	CTNA

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS
APIDRA

	+ SANOFI AVENTIS US	1000 UNITS/10ML (100 UNITS/ML)	N21629	001	Apr 16, 2004	Mar	CMFD
	+	300 UNITS/3ML (100 UNITS/ML)	N21629	002	Dec 20, 2005	Mar	CMFD

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

EXUBERA

	PFIZER	1MG/INH	N21868	001	Jan 27, 2006	Jan	NEWA
+		3MG/INH	N21868	002	Jan 27, 2006	Jan	NEWA

ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

AP	SANDOZ	100MG/ML	N40648	001	Jul 05, 2005	Jan	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

AB	WEST WARD	30MG	N76813	002	Mar 30, 2006	Mar	NEWA

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

>D>		ABRIKA PHARMS	5MG	N77317	002	Jan 05, 2006	Apr	CTEC
>A>	AB		5MG	N77317	002	Jan 05, 2006	Apr	CTEC
>A>	AB	AMIDE PHARM	2.5MG	N77169	001	Apr 24, 2006	Apr	NEWA
>A>	AB		5MG	N77169	002	Apr 24, 2006	Apr	NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	SANDOZ	15MG/ML	N76271	001	Oct 06, 2004	Jan	CAHN
AP		30MG/ML	N76271	002	Oct 06, 2004	Jan	CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

>A>		KETOTIFEN FUMARATE						
>A>	AT	APOTEX	EQ 0.025% BASE	N77354	001	May 09, 2006	Apr	NEWA
		ZADITOR						
>D>	+	NOVARTIS	EQ 0.025% BASE	N21066	001	Jul 02, 1999	Apr	CFTG
>A>	AT	+	EQ 0.025% BASE	N21066	001	Jul 02, 1999	Apr	CFTG

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

TAP PHARM	15MG,N/A;N/A,250MG	N21507	002	Nov 14, 2003	Feb	CTNA

PREVACID NAPRAPAC 375 (COPACKAGED)

TAP PHARM	15MG,N/A;N/A,375MG	N21507	003	Nov 14, 2003	Feb	CTNA

PREVACID NAPRAPAC 500 (COPACKAGED)

+ TAP PHARM	15MG,N/A;N/A,500MG	N21507	004	Nov 14, 2003	Feb	CTNA

LEVETIRACETAM

TABLET; ORAL

KEPPRA

UCB INC	750MG	N21035	003	Nov 30, 1999	Mar	CRLD
+	1GM	N21035	004	Jan 06, 2006	Mar	NEWA

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

	@ ALCON	EQ 0.5% BASE	N21114	001	Feb 23, 2000	Feb	CAHN

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL

ANESTACON

AT	+ POLYMEDICA	2%	N80429	001		Jan	CDFR

LIDOCAINE; TETRACAINE

PATCH; TOPICAL

SYNERA

	+ ENDO PHARMS	70MG;70MG	N21623	001	Jun 23, 2005	Feb	CAHN

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	AUROBINDO	2.5MG	N77622	001	Feb 22, 2006	Feb	NEWA
AB		5MG	N77622	002	Feb 22, 2006	Feb	NEWA
AB		10MG	N77622	003	Feb 22, 2006	Feb	NEWA
AB		20MG	N77622	004	Feb 22, 2006	Feb	NEWA
AB		30MG	N77622	005	Feb 22, 2006	Feb	NEWA
AB		40MG	N77622	006	Feb 22, 2006	Feb	NEWA

LORAZEPAM

TABLET; ORAL

LORAZEPAM

AB	MYLAN	0.5MG	N77657	001	Mar 16, 2006	Mar	NEWA
AB		1MG	N77657	002	Mar 16, 2006	Mar	NEWA
AB		2MG	N77657	003	Mar 16, 2006	Mar	NEWA
>A> AB	VINTAGE PHARMS	0.5MG	N77754	001	May 10, 2006	Apr	NEWA
>A> AB		1MG	N77754	002	May 10, 2006	Apr	NEWA
>A> AB		2MG	N77754	003	May 10, 2006	Apr	NEWA

LOVASTATIN

TABLET; ORAL

LOVASTATIN

>A> AB	MUTUAL PHARM	10MG	N77520	001	Apr 14, 2006	Apr	NEWA
>A> AB		20MG	N77520	002	Apr 14, 2006	Apr	NEWA
>A> AB		40MG	N77520	003	Apr 14, 2006	Apr	NEWA

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL

ADVICOR

	+ KOS LIFE	20MG;750MG	N21249	002	Dec 17, 2001	Feb	CMFD

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

	+ SUCAMPO PHARMS	24UGM	N21908	001	Jan 31, 2006	Jan	NEWA

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET, CHEWABLE; ORAL

ZEGERID

		SANTARUS	700MG;20MG;600MG	N21850	001	Mar 24, 2006	Mar	NEWA
	+		700MG;40MG;600MG	N21850	002	Mar 24, 2006	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

	+	PHARMACIA AND UPJOHN	104MG/0.65ML	N21583	001	Dec 17, 2004	Jan	CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB		APOTEX	40MG/ML	N77404	001	Feb 16, 2006	Jan	NEWA

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

		@ ROXANE	600MG	N84332	001		Jan	DISC
		@ SANDOZ	200MG	N14547	002		Jan	DISC
		@	400MG	N14547	001		Jan	DISC
		@	400MG	N80655	001		Jan	DISC
		@ SCHERER LABS	400MG	N83343	001		Jan	DISC
		@ TABLICAPS	400MG	N83494	001		Jan	DISC
AA	+	WATSON LABS	200MG	N83304	001		Jan	CRLD
		@	200MG	N85720	001		Jan	DISC
	+		400MG	N83308	001		Jan	CRLD
		@	400MG	N85721	001		Jan	DISC

MILTOWN

		@ MEDPOINTE PHARM HLC	200MG	N09698	004		Jan	DISC
		@	400MG	N09698	002		Jan	DISC

TRANMEP

		@ SOLVAY	400MG	N16249	001		Jan	DISC

MESALAMINE

ENEMA; RECTAL

ROWASA

>A>	AB	+ ALAVEN PHARM	4GM/60ML	N19618	001	Dec 24, 1987	Apr	CAHN
>D>	AB	+ SOLVAY	4GM/60ML	N19618	001	Dec 24, 1987	Apr	CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

	BX	DEPOMED INC	500MG	N21748	001	Jun 03, 2005	Jan	CAHN
	BX		1GM	N21748	002	Jun 03, 2005	Jan	CAHN

METFORMIN HYDROCHLORIDE

	AB	SUN PHARM INDS (IN)	500MG	N77336	001	Feb 09, 2006	Jan	NEWA
	AB		750MG	N77336	002	Feb 09, 2006	Jan	NEWA

>D> METHOTREXATE

>D> INJECTABLE; INJECTION

>D> METHOTREXATE PRESERVATIVE FREE

>D>	+	BEDFORD	EQ 1GM BASE/VIAL	N40632	001	Aug 12, 2005	Apr	CAIN

>A>			METHOTREXATE SODIUM						
>A>			INJECTABLE; INJECTION						
>A>			METHOTREXATE PRESERVATIVE FREE						
>A>		+	BEDFORD	EQ 1GM BASE/VIAL	N40632	001	Aug 12, 2005	Apr	CAIN
>D>	AP	+	MAYNE PHARMA USA	ED 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	CPOT
>A>		+		EQ 1GM BASE/40ML (25 MG/ML)	N11719	012	Apr 13, 2005	Apr	CPOT
			METHOTREXATE SODIUM						
>D>	AP		BEDFORD	EQ 50 MG BASE/2ML (25 ML/ML)	N89340	001	Sep 16, 1986	Apr	CPOT
>A>	AP	+		EQ 50MG BASE/2ML (25MG/ML)	N89340	001	Sep 16, 1986	Apr	CPOT
>D>	AP			EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16, 1986	Apr	CTEC
>A>		+		EQ 100MG BASE/4ML (25 MG/ML)	N89341	001	Sep 16, 1986	Apr	CTEC
>D>	AP			EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16, 1986	Apr	CTEC
>A>		+		EQ 200MG BASE/8ML (25 MG/ML)	N89342	001	Sep 16, 1986	Apr	CTEC
>D>	AP			EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16, 1986	Apr	CTEC
>A>		+		EQ 250MG BASE/10ML (25 MG/ML)	N89343	001	Sep 16, 1986	Apr	CTEC
			METHYLPHENIDATE						
>A>			FILM, EXTENDED RELEASE; TRANSDERMAL						
>A>			DAYTRANA						
>A>		+	SHIRE	10MG/9HR (1.1MG/HR)	N21514	001	Apr 06, 2006	Apr	NEWA
>A>		+		15MG/9HR (1.6MG/HR)	N21514	002	Apr 06, 2006	Apr	NEWA
>A>		+		20MG/9HR (2.2MG/HR)	N21514	003	Apr 06, 2006	Apr	NEWA
>A>		+		30MG/9HR (3.3MG/HR)	N21514	004	Apr 06, 2006	Apr	NEWA
			METHYLPHENIDATE HYDROCHLORIDE						
			CAPSULE, EXTENDED RELEASE; ORAL						
			METADATE CD						
	BX		UCB INC	40MG	N21259	004	Feb 19, 2006	Feb	NEWA
				50MG	N21259	005	Feb 19, 2006	Feb	NEWA
		+		60MG	N21259	006	Feb 19, 2006	Feb	NEWA
			RITALIN LA						
	BX	+	NOVARTIS	40MG	N21284	003	Jun 05, 2002	Feb	CTEC
			METOCLOPRAMIDE HYDROCHLORIDE						
			TABLET; ORAL						
			METOCLOPRAMIDE HYDROCHLORIDE						
>D>			@ MUTUAL PHARM	EQ 5MG BASE	N71536	002	Jan 16, 1997	Apr	CMFD
>A>	AB			EQ 5MG BASE	N71536	002	Jan 16, 1997	Apr	CMFD
>D>			@	EQ 10MG BASE	N71536	001	Apr 28, 1993	Apr	CMFD
>A>	AB			EQ 10MG BASE	N71536	001	Apr 28, 1993	Apr	CMFD
			MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE						
			OINTMENT; TOPICAL						
			VUSION						
		+	BARRIER	0.25%;81.35%;15%	N21026	001	Feb 16, 2006	Feb	NEWA
			MIDAZOLAM HYDROCHLORIDE						
			INJECTABLE; INJECTION						
			MIDAZOLAM HYDROCHLORIDE						
	AP	+	HOSPIRA	EQ 5MG BASE/ML	N75293	002	Jun 20, 2000	Mar	CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

MINOCIN

AB		TRIAX PHARMS	EQ 50MG BASE	N50649	001	May 31, 1990	Feb	CAHN
	@		EQ 75MG BASE	N50649	003	Feb 12, 2001	Feb	CAHN
AB	+		EQ 100MG BASE	N50649	002	May 31, 1990	Feb	CAHN

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

AB		AUROBINDO PHARMA LTD	45MG	N77376	004	Feb 28, 2006	Feb	NEWA
AB		BARR	45MG	N76307	003	Feb 28, 2006	Feb	NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE

AP		AM PHARM	EQ 20MG BASE/10ML (2MG/ML)	N77496	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N77496	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N77496	003	Apr 11, 2006	Mar	NEWA
AP		BEDFORD	EQ 20MG BASE/10ML (2MG/ML)	N76611	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N76611	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N76611	003	Apr 11, 2006	Mar	NEWA
AP		MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)	N76871	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N76871	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N76871	003	Apr 11, 2006	Mar	NEWA
AP		SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)	N77356	001	Apr 11, 2006	Mar	NEWA
AP			EQ 25MG BASE/12.5ML (2MG/ML)	N77356	002	Apr 11, 2006	Mar	NEWA
AP			EQ 30MG BASE/15ML (2MG/ML)	N77356	003	Apr 11, 2006	Mar	NEWA

NOVANTRONE

AP	+	SERONO INC	EQ 20MG BASE/10ML(2MG/ML)	N19297	001	Dec 23, 1987	Mar	CFTG
AP	+		EQ 25MG BASE/12.5ML (2MG/ML)	N19297	002	Dec 23, 1987	Mar	CFTG
AP	+		EQ 30MG BASE/15ML (2MG/ML)	N19297	003	Dec 23, 1987	Mar	CFTG

MOMETASONE FUROATE

LOTION; TOPICAL

MOMETASONE FUROATE

AB		PERRIGO	0.1%	N77180	001	Apr 06, 2005	Mar	CAHN
AB		TARO	0.1%	N76788	001	Mar 15, 2006	Feb	NEWA

MORPHINE SULFATE

INJECTABLE; INJECTION

MORPHINE SULFATE

		HOSPIRA	5MG/ML	N19916	002	Mar 30, 2006	Mar	NEWA

NABUMETONE

TABLET; ORAL

NABUMETONE

>D>	AB	IVAX PHARMS	500MG	N76009	001	Jan 24, 2003	Apr	CAHN
>D>	AB		750MG	N76009	002	Jan 24, 2003	Apr	CAHN
>A>	AB	PAR PHARM	500MG	N76009	001	Jan 24, 2003	Apr	CAHN
>A>	AB		750MG	N76009	002	Jan 24, 2003	Apr	CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

>D>	AP		SANDOZ	EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Apr	CRLD
>A>	AP	+		EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Apr	CRLD
>D>	AP			EQ 1GM BASE/VIAL	N62732	001	Dec 23, 1986	Apr	CRLD
>A>	AP	+		EQ 1GM BASE/VIAL	N62732	001	Dec 23, 1986	Apr	CRLD
>D>	AP			EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Apr	CRLD
>A>	AP	+		EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Apr	CRLD
>D>	AP			EQ 2GM BASE/VIAL	N62732	002	Dec 23, 1986	Apr	CRLD
>A>	AP	+		EQ 2GM BASE/VIAL	N62732	002	Dec 23, 1986	Apr	CRLD
>D>	AP			EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Apr	CRLD
>A>	AP	+		EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Apr	CRLD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
VIVITROL

>A>		+	ALKERMES	380MG/VIAL	N21897	001	Apr 13, 2006	Apr	NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION
NEOSPORIN AND POLYMYXIN B SULFATE

	AT		X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106	001	Jan 31, 2006	Jan	NEWA
	AT			EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108	001	Jan 31, 2006	Jan	NEWA

NEOSPORIN G.U. IRRIGANT

	AT	+	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001		Jan	CTEC
	AT	+		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707	002		Jan	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HYDROCHLORIDE

>A>	AB		BARR	20MG	N74439	001	Dec 10, 1996	Apr	CAHN
>A>	AB			30MG	N74439	002	Dec 10, 1996	Apr	CAHN
>D>	AB		IVAX PHARMS	20MG	N74439	001	Dec 10, 1996	Apr	CAHN
>D>	AB			30MG	N74439	002	Dec 10, 1996	Apr	CAHN

INJECTABLE; INJECTION
CARDENE

		+	PDL BIOPHARMA INC	2.5MG/ML	N19734	001	Jan 30, 1992	Jan	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
AFEDITAB CR

	AB1		WATSON LABS	30MG	N75128	001	Mar 10, 2000	Jan	CAHN
	AB1			60MG	N75659	001	Oct 26, 2001	Jan	CAHN

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE

	AP		AM PHARM	EQ 0.2MG BASE/ML	N77450	001	Feb 10, 2006	Jan	NEWA
	AP			EQ 1MG BASE/ML	N77450	002	Feb 10, 2006	Jan	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

	AP		AM PHARM	EQ 0.05MG BASE/ML	N77457	001	Feb 10, 2006	Jan	NEWA

INJECTABLE; INJECTION
OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	AM PHARM	EQ 0.1MG BASE/ML	N77457	002	Feb 10, 2006	Jan	NEWA
AP		EQ 0.5MG BASE/ML	N77457	003	Feb 10, 2006	Jan	NEWA

OFLOXACIN

TABLET; ORAL
OFLOXACIN

AB	DR REDDYS LABS LTD	200MG	N77098	001	Feb 10, 2006	Jan	NEWA
AB		300MG	N77098	002	Feb 10, 2006	Jan	NEWA
AB		400MG	N77098	003	Feb 10, 2006	Jan	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL
ZEGERID

	SANTARUS	20MG;1.1GM	N21849	001	Feb 27, 2006	Feb	NEWA
+		40MG;1.1GM	N21849	002	Feb 27, 2006	Feb	NEWA

FOR SUSPENSION; ORAL
ZEGERID

	SANTARUS	20MG/PACKET;1.68GM/PACKET	N21636	001	Jun 15, 2004	Feb	CAIN
+		40MG/PACKET;1.68GM/PACKET	N21706	001	Dec 21, 2004	Feb	CAIN

OXYMETHOLONE

TABLET; ORAL
ANADROL-50

>A>	+	ALAVEN PHARM	50MG	N16848	001		Apr	CAHN
>D>	+	UNIMED PHARMS	50MG	N16848	001		Apr	CAHN

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)
ABRAXANE

>A>	+	ABRAXIS BIOSCIENCE	100MG/VIAL	N21660	001	Jan 07, 2005	Apr	CAHN
>D>	+	AM BIOSCIENCE	100MG/VIAL	N21660	001	Jan 07, 2005	Apr	CAHN

PAROXETINE MESYLATE

TABLET; ORAL
PEXEVA

>A>		JDS PHARMS	EQ 10MG BASE	N21299	001	Jul 03, 2003	Apr	CAHN
>A>			EQ 20MG BASE	N21299	002	Jul 03, 2003	Apr	CAHN
>A>			EQ 30MG BASE	N21299	003	Jul 03, 2003	Apr	CAHN
>A>	+		EQ 40MG BASE	N21299	004	Jul 03, 2003	Apr	CAHN
>D>		SYNTHON PHARMS	EQ 10MG BASE	N21299	001	Jul 03, 2003	Apr	CAHN
>D>			EQ 20MG BASE	N21299	002	Jul 03, 2003	Apr	CAHN
>D>			EQ 30MG BASE	N21299	003	Jul 03, 2003	Apr	CAHN
>D>	+		EQ 40MG BASE	N21299	004	Jul 03, 2003	Apr	CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL
PENICILLIN V POTASSIUM

AA	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529	001		Jan	CAHN
AA		EQ 250MG BASE/5ML	N61529	002		Jan	CAHN

TABLET; ORAL
PENICILLIN V POTASSIUM

	@ AM ANTIBIOTICS	EQ 250MG BASE	N61528	001		Jan	CAHN
	@	EQ 500MG BASE	N61528	002		Jan	CAHN

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

>A>	AB	PAR PHARM	EQ 0.05MG BASE	N76061	001	Nov 27, 2002	Apr	CAHN
>A>	AB		EQ 0.25MG BASE	N76061	002	Nov 27, 2002	Apr	CAHN
>A>	AB		EQ 1MG BASE	N76061	003	Nov 27, 2002	Apr	CAHN
>D>	AB	TEVA	EQ 0.05MG BASE	N76061	001	Nov 27, 2002	Apr	CAHN
>D>	AB		EQ 0.25MG BASE	N76061	002	Nov 27, 2002	Apr	CAHN
>D>	AB		EQ 1MG BASE	N76061	003	Nov 27, 2002	Apr	CAHN

PERMAX

	AB	VALEANT	EQ 0.05MG BASE	N19385	001	Dec 30, 1988	Jan	CRLD
	AB	+	EQ 0.25MG BASE	N19385	002	Dec 30, 1988	Jan	CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC PLAIN

		+ ALPHARMA US PHARMS	5MG/5ML;6.25MG/5ML	N88761	001	Nov 08, 1984	Jan	CTEC

PROMETHAZINE VC PLAIN

		@ MORTON GROVE	5MG/5ML;6.25MG/5ML	N88897	001	Jan 04, 1985	Jan	DISC

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

		@ MERCK	1MG/0.5ML	N12223	002		Feb	DISC
		@	10MG/ML	N12223	001		Feb	DISC

VITAMIN K1

	BP	+ HOSPIRA	1MG/0.5ML	N87954	001	Jul 25, 1983	Feb	CRLD
		+	10MG/ML	N87955	001	Jul 25, 1983	Feb	CRLD

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

	AB	IMPAX LABS	5MG	N77248	001	Mar 31, 2006	Mar	NEWA
	AB		7.5MG	N77248	002	Mar 31, 2006	Mar	NEWA

SALAGEN

	AB	+ MGI PHARMA INC	7.5MG	N20237	002	Apr 18, 2003	Mar	CFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

>A>	AA	TEVA PHARMS	17GM/SCOOPFUL	N77445	001	May 04, 2006	Apr	NEWA

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

	AB	UPSHER SMITH	8MEQ	N19123	001	Apr 17, 1986	Jan	CRLD

POTASSIUM CHLORIDE

	AB	+ COPLEY PHARM	8MEQ	N70618	001	Sep 09, 1987	Jan	CRLD

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

>D>		BRISTOL MYERS SQUIBB	10MG	N19898	002	Oct 31, 1991	Apr	CFTG
>A>	AB		10MG	N19898	002	Oct 31, 1991	Apr	CFTG

TABLET; ORAL
PRAVACHOL
>D> BRISTOL MYERS SQUIBB 20MG N19898 003 Oct 31, 1991 Apr CFTG
>A> AB 20MG N19898 003 Oct 31, 1991 Apr CFTG
>D> 40MG N19898 004 Mar 22, 1993 Apr CFTG
>A> AB 40MG N19898 004 Mar 22, 1993 Apr CFTG
>A> PRAVASTATIN SODIUM
>A> AB TEVA 10MG N76056 001 Apr 24, 2006 Apr NEWA
>A> AB 20MG N76056 002 Apr 24, 2006 Apr NEWA
>A> AB 40MG N76056 003 Apr 24, 2006 Apr NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
PRAZOSIN HYDROCHLORIDE
@ CLONMEL HLTHCARE EQ 1MG BASE N72705 001 May 16, 1989 Jan DISC
@ EQ 5MG BASE N72707 001 May 16, 1989 Jan DISC

PREDNISOLONE ACETATE

INJECTABLE; INJECTION
PREDNISOLONE ACETATE
@ STERIS 25MG/ML N83398 001 Mar DISC
@ 50MG/ML N83764 001 Mar DISC

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL
PHENERGAN
@ WYETH PHARMS INC 12.5MG N10926 002 Mar DISC
@ 25MG N10926 001 Mar DISC
PROMETHAZINE HYDROCHLORIDE
AB + G AND W LABS 25MG N40428 001 Feb 05, 2002 Mar CRLD
PROMETHEGAN
+ G AND W LABS 50MG N87165 001 Aug 14, 1987 Jan CRLD
SYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE
>A> AA VINTAGE 6.25MG/5ML N40643 001 Apr 26, 2006 Apr NEWA

PROPOFOL

INJECTABLE; INJECTION
PROPOFOL
AB HOSPIRA 10MG/ML N77908 001 Mar 17, 2006 Mar NEWA

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
PROPOXYPHENE HYDROCHLORIDE
AA PAR PHARM 65MG N80269 001 Mar CAHN

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
PROPRANOLOL HYDROCHLORIDE
AP SANDOZ 1MG/ML N76400 001 Feb 26, 2003 Jan CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
REGONOL
AP SANDOZ 5MG/ML N17398 001 Jan CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

AB		TORPHARM	EQ 5MG BASE	N76240	001	Jan 26, 2006	Jan	NEWA
AB			EQ 10MG BASE	N76240	002	Jan 26, 2006	Jan	NEWA
AB			EQ 20MG BASE	N76240	003	Jan 26, 2006	Jan	NEWA
AB			EQ 40MG BASE	N76240	004	Jan 26, 2006	Jan	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE GLUCONATE

BX	+	MUTUAL PHARM	324MG	N89338	001	Feb 11, 1987	Jan	CTEC
BX		WATSON LABS	324MG	N87810	001	Sep 29, 1982	Jan	CMFD

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

		@ CLONMEL HLTHCARE	200MG	N87011	001		Jan	DISC
		@ LANNETT	200MG	N83743	001		Jan	DISC
		@ MUTUAL PHARM	100MG	N81029	001	Apr 14, 1989	Jan	DISC
		@ PHARM FORM	200MG	N83808	001		Jan	DISC
		@ SANDOZ	200MG	N84631	001		Jan	DISC
		@	200MG	N84914	001		Jan	DISC
AB			200MG	N88072	002		Jan	NEWA
		@	300MG	N89839	001	Sep 29, 1988	Jan	DISC
		@ WATSON LABS	200MG	N83288	001		Jan	DISC
		@	200MG	N85140	002		Jan	DISC

RANITIDINE

INJECTABLE; INJECTION
RANITIDINE

AP		BEDFORD	EQ 25MG BASE/ML	N77458	001	Feb 16, 2006	Feb	NEWA

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL
RANEXA

	+	CV THERAP	500MG	N21526	002	Jan 27, 2006	Jan	NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERDAL

		JANSSEN PHARMA	3MG	N21444	004	Dec 23, 2004	Mar	CMFD
			4MG	N21444	005	Dec 23, 2004	Mar	CMFD

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL
EMSAM

		SOMERSET	6MG/24HR	N21336	001	Feb 27, 2006	Mar	CAIN
			9MG/24HR	N21336	002	Feb 27, 2006	Mar	CAIN
	+		12MG/24HR	N21336	003	Feb 27, 2006	Mar	CAIN

SELEGILINE HYDROCHLORIDE

FILM, EXTENDED RELEASE; TRANSDERMAL

	EMSAM							
	SOMERSET	6MG/24HR	N21336	001	Feb 27, 2006	Feb		NEWA
		9MG/24HR	N21336	002	Feb 27, 2006	Feb		NEWA
+		12MG/24HR	N21336	003	Feb 27, 2006	Feb		NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

	OSMOPREP							
+	SALIX PHARMS	0.398GM;1.102GM	N21892	001	Mar 16, 2006	Mar		NEWA

SPIRONOLACTONE

TABLET; ORAL

	SPIRONOLACTONE							
AB	PUREPAC PHARM	25MG	N40353	003	Mar 15, 2006	Feb		NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION

	ANECTINE							
AP	+ SANDOZ	20MG/ML	N08453	002		Jan		CAHN
	@	50MG/ML	N08453	003		Jan		CAHN
	@	500MG/VIAL	N08453	001		Jan		CAHN
	@	1GM/VIAL	N08453	004		Jan		CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

	SULFACETAMIDE SODIUM							
>A> AT	ALCON	30%	N89068	001	May 05, 1987	Apr		CAHN
>D> AT	STERIS	30%	N89068	001	May 05, 1987	Apr		CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

	BACTRIM PEDIATRIC							
>D>	@ MUTUAL PHARM	200MG/5ML;40MG/5ML	N17560	002		Apr		CMFD
>A> AB		200MG/5ML;40MG/5ML	N17560	002		Apr		CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

	IMITREX							
+	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)	N20080	001	Dec 28, 1992	Feb		CDFR
	IMITREX STATDOSE							
+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (8MG/ML)	N20080	002	Feb 01, 2006	Feb		NEWA
+		EQ 6MG BASE/0.5ML (12MG/ML)	N20080	003	Dec 23, 1996	Feb		NEWA

SUNITINIB MALATE

CAPSULE; ORAL

	SUTENT							
	PFIZER	12.5MG	N21938	001	Jan 26, 2006	Jan		NEWA
		25MG	N21938	002	Jan 26, 2006	Jan		NEWA
+		50MG	N21938	003	Jan 26, 2006	Jan		NEWA

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

>D>			BERLEX LABS	N/A	N20887	001	Sep 14, 1998	Apr	CAHN
>A>			CIS BIO INTL SA	N/A	N20887	001	Sep 14, 1998	Apr	CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

>D>		+	BERLEX LABS	N/A	N21012	001	Aug 03, 1999	Apr	CAHN
>A>		+	CIS BIO INTL SA	N/A	N21012	001	Aug 03, 1999	Apr	CAHN

TERCONAZOLE

SUPPOSITORY; VAGINAL

TERAZOL 3

	AB	+	ORTHO MCNEIL PHARM	80MG	N19641	001	May 24, 1988	Mar	CFTG

TERCONAZOLE

	AB		PERRIGO NEW YORK	80MG	N77149	001	Mar 17, 2006	Mar	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

	AB	+	UNIMED PHARMS	1%	N21015	001	Feb 28, 2000	Jan	CTEC

TESTOSTERONE

	AB		WATSON LABS	1%	N76737	001	Jan 27, 2006	Jan	NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DELATESTRYL

	AO	+	INDEVUS PHARMS	200MG/ML	N09165	003		Jan	CAHN
			@	200MG/ML	N09165	001		Jan	CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

>D>			@ CLONMEL HLTHCARE	250MG	N50278	003		Apr	CAHN
>D>			@	500MG	N50278	001		Apr	CAHN
>A>			@ SCIREG INTL INC	250MG	N50278	003		Apr	CAHN
>A>			@	500MG	N50278	001		Apr	CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

	AP		TRACE RADIOCHEMICALS	1mCi/ML	N75569	001	Nov 21, 2001	Feb	CAHN

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

>A>	AB		NOSTRUM	400MG	N40595	001	Apr 21, 2006	Apr	NEWA
>A>	AB			600MG	N40560	002	Apr 21, 2006	Apr	NEWA

UNIPHYL

>D>		+	PURDUE FREDERICK	400MG	N87571	001	Sep 01, 1982	Apr	CTEC
>A>	AB	+		400MG	N87571	001	Sep 01, 1982	Apr	CTEC
>D>		+		600MG	N40086	001	Apr 15, 1996	Apr	CTEC

TABLET, EXTENDED RELEASE; ORAL
UNIPHYL

>A>	AB	+	PURDUE FREDERICK	600MG	N40086	001	Apr 15, 1996	Apr	CTEC

TINIDAZOLE

TABLET; ORAL
TINDAMAX

			MISSION PHARMA	250MG	N21618	001	May 17, 2004	Jan	CAHN
		+		500MG	N21618	002	May 17, 2004	Jan	CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

		@	IVAX PHARMS	50MG	N75963	001	Jul 03, 2002	Jan	DISC

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT

		@	SANDOZ	25MG/ML	N11685	003		Jan	CAHN
		@		40MG/ML	N12802	001		Jan	CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION
ARISTOSPAN

		+	SANDOZ	5MG/ML	N16466	001		Jan	CAHN
		+		20MG/ML	N16466	002		Jan	CAHN

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
PBZ

		@	NOVARTIS	50MG	N05914	002		Jan	DISC

TROLEANDOMYCIN

CAPSULE; ORAL
TAO

		@	PFIZER	EQ 250MG BASE	N50336	002		Mar	DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA

		+	R TECH UENO LTD	0.15%	N21214	001	Aug 03, 2000	Feb	CAHN

UROKINASE

INJECTABLE; INJECTION
ABBOKINASE

>D>		@	ABBOTT	5,000 IU/VIAL	N21846	003		Apr	CAHN
>D>		@		9,000 IU/VIAL	N21846	002		Apr	CAHN
>D>		+		250,000 IU/VIAL	N21846	001		Apr	CAHN
>A>		@	IMARX THERAP	5,000 IU/VIAL	N21846	003		Apr	CAHN
>A>		@		9,000 IU/VIAL	N21846	002		Apr	CAHN
>A>		+		250,000 IU/VIAL	N21846	001		Apr	CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

AP	+	BEDFORD	20MG/VIAL	N75549	002	Jun 13, 2000	Jan	CRLD

ZIDOVUDINE

CAPSULE; ORAL
RETROVIR

AB	+	GLAXOSMITHKLINE	100MG	N19655	001	Mar 19, 1987	Mar	CFTG

ZIDOVUDINE

AB		AUROBINDO PHARMA LTD	100MG	N78128	001	Mar 27, 2006	Mar	NEWA

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL
GEODON

	+	PFIZER INC	EQ 10MG BASE/ML	N21483	001	Mar 29, 2006	Mar	NEWA

ZONISAMIDE

CAPSULE; ORAL
ZONISAMIDE

	AB		GLENMARK PHARMS	25MG	N77651	001	Jan 30, 2006	Jan	NEWA
	AB			50MG	N77651	002	Jan 30, 2006	Jan	NEWA
	AB			100MG	N77651	003	Jan 30, 2006	Jan	NEWA
	AB		SUN PHARM INDS (IN)	25MG	N77634	001	Mar 17, 2006	Mar	NEWA
	AB			50MG	N77634	002	Mar 17, 2006	Mar	NEWA
	AB			100MG	N77634	003	Mar 17, 2006	Mar	NEWA
>A>	AB		WATSON LABS	25MG	N77650	001	Apr 20, 2006	Apr	NEWA
>A>	AB			50MG	N77650	002	Apr 20, 2006	Apr	NEWA
>A>	AB			100MG	N77650	003	Apr 20, 2006	Apr	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP WITH TINT

>A>	+	MEDI FLEX INC	2%;70% (10.5ML)	N20832	005	Apr 03, 2006	Apr	NEWA

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

		ALPHARMA US PHARMS	5.2MG/SPRAY	N74800	001	Jul 26, 2001	Jan	CPOT
	+	BAUSCH AND LOMB	5.2MG/SPRAY	N75702	001	Jul 03, 2001	Jan	CRLD

NASALCROM

	@	PHARMACIA UPJOHN	5.2MG/SPRAY	N20463	001	Jan 03, 1997	Jan	DISC

KETOPROFEN

TABLET; ORAL

ACTRON

	@	BAYER	12.5MG	N20499	001	Oct 06, 1995	Feb	DISC

ORUDIS KT

	@	WYETH CONS	12.5MG	N20429	001	Oct 06, 1995	Feb	DISC

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

IMODIUM A-D

	+	MCNEIL	1MG/7.5ML	N19487	002	Jul 08, 2004	Mar	CDFR

LORATADINE

TABLET; ORAL

LORATADINE

		APOTEX	10MG	N76471	001	Feb 14, 2006	Jan	NEWA

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MEN'S ROGAINE

	+	PHARMACIA AND UPJOHN	5%	N21812	001	Jan 20, 2006	Jan	NEWA

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

	+	BANNER PHARMACAPS	EQ 200MG BASE	N21920	001	Feb 17, 2006	Feb	NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

>D>		GLAXOSMITHKLINE	EQ 2MG BASE	N18612	003	Dec 23, 1998	Apr	CTNA
			EQ 2MG BASE	N18612	004	Sep 25, 2000	Mar	CRLD
			EQ 2MG BASE	N18612	003	Dec 23, 1998	Mar	CRLD
>D>			EQ 4MG BASE	N20066	003	Dec 23, 1998	Apr	CTNA
			EQ 4MG BASE	N20066	003	Dec 23, 1998	Mar	CRLD
			EQ 4MG BASE	N20066	004	Sep 25, 2000	Mar	CRLD

NICORETTE (MINT)

>A>		GLAXOSMITHKLINE	EQ 2MG BASE	N18612	003	Dec 23, 1998	Apr	CTNA
>A>			EQ 4MG BASE	N20066	003	Dec 23, 1998	Apr	CTNA

GUM, CHEWING; BUCCAL

>A> NICOTINE POLACRILEX

>A>	PERRIGO	EQ 2MG BASE	N76776	001	Sep 16, 2004	Apr	CTNA
>A>		EQ 2MG BASE	N76777	001	Sep 16, 2004	Apr	CTNA
>A>		EQ 4MG BASE	N76778	001	Sep 16, 2004	Apr	CTNA
>A>		EQ 4MG BASE	N76779	001	Sep 16, 2004	Apr	CTNA
>A>	WATSON LABS	EQ 2MG BASE	N76569	001	Jul 29, 2004	Apr	CTNA
>A>		EQ 4MG BASE	N76568	002	Jul 29, 2004	Apr	CTNA

>D> NICOTINE POLACRILEX (MINT)

>D>	PERRIGO	EQ 2MG BASE	N76777	001	Sep 16, 2004	Apr	CTNA
>D>		EQ 4MG BASE	N76779	001	Sep 16, 2004	Apr	CTNA
>D>	WATSON LABS	EQ 2MG BASE	N76569	001	Jul 29, 2004	Apr	CTNA
>D>		EQ 4MG BASE	N76568	002	Jul 29, 2004	Apr	CTNA

>D> NICOTINE POLACRILEX (ORANGE)

>D>	PERRIGO	EQ 2MG BASE	N76776	001	Sep 16, 2004	Apr	CTNA
>D>		EQ 4MG BASE	N76778	001	Sep 16, 2004	Apr	CTNA

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

	PERRIGO R AND D	EQ 2MG BASE	N77007	001	Jan 31, 2006	Jan	NEWA
		EQ 4MG BASE	N77007	002	Jan 31, 2006	Jan	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE

	WOCKHARDT	EQ 75MG BASE	N76760	001	Feb 24, 2006	Feb	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2006

NO APRIL 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO APRIL 2006 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM								
021652 001		5034394	Dec 18, 2011	DS	DP		D-40	Aug 02, 2007
		5034394*PED	Jun 18, 2012					
		5047407	Nov 17, 2009	DS	DP	U-257		
		5047407*PED	May 17, 2010					
		5089500	Jun 26, 2009			U-257		
		5089500*PED	Dec 26, 2009					
		5905082	May 18, 2016	DS	DP			
		5905082*PED	Nov 18, 2016					
		6294540	May 14, 2018	DS	DP	U-257		
		6294540*PED	Nov 14, 2018					
ALBUTEROL SULFATE - PROAIR HFA								
021457 001							I-235	Feb 03, 2009
ALBUTEROL SULFATE - VENTOLIN HFA								
020983 001	**>A>**	6131566	Apr 14, 2015		DP	U-716		
	>A>	6131566	Apr 14, 2015		DP	U-589		
	>A>	6532955	Apr 14, 2015		DP	U-716		
	>A>	6532955	Apr 14, 2015		DP	U-590		
ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D								
021762 001							NC	Apr 07, 2008
ALFUZOSIN HYDROCHLORIDE - UROXATRAL								
021287 001		4661491	May 27, 2007			U-706		
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL								
020364 006							**>A>** NS	Apr 11, 2009
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL								
020364 007							**>A>** NS	Apr 11, 2009
ANIDULAFUNGIN - ERAXIS								
021632 001		5965525	Oct 12, 2016	DS	DP	U-540	NCE	Feb 17, 2011
		6384013	Mar 19, 2012	DS				
		6743777	Mar 19, 2012		DP	U-540		
		6960564	Apr 12, 2021		DP	U-540		
APREPITANT - EMEND								
021549 001		5145684	Jan 25, 2011		DP			
APREPITANT - EMEND								
021549 002		5145684	Jan 25, 2011		DP			
ARIPIPRAZOLE - ABILIFY								
021436 001							I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY								
021436 002							I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY								
021436 003							I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY								
021436 004							I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY								
021436 005							I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY								
021436 006							I-488	Mar 01, 2008
ARIPIPRAZOLE - ABILIFY								
021713 001		6977257	Apr 24, 2022	DS	DP		I-488	Mar 01, 2008
ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - SEPTOCAINE								
022010 001							**>A>** NP	Mar 30, 2009
AZELASTINE HYDROCHLORIDE - ASTELIN								
020114 001							D-102	Feb 17, 2009
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX								
021852 001		4866048	Dec 29, 2007	DS	DP	U-88	NC	Jan 09, 2009
		4866048	Dec 29, 2007	DS	DP	U-193		
		5763426	Jun 09, 2015	DS	DP			
		6753013	Jan 27, 2020		DP	U-88		
		6753013	Jan 27, 2020		DP	U-193		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BIVALIRUDIN - ANGIOMAX					
020873 001				I-486	Nov 30, 2008
BORTEZOMIB - VELCADE					
021602 001				ODE	Mar 25, 2012
BRIMONIDINE TARTRATE - ALPHAGAN P					
021770 001	5424078	Jun 13, 2012	DP		
	5424078*PED	Dec 13, 2012			
	6562873	Jul 10, 2021	DP		
	6562873*PED	Jan 10, 2022			
	6627210	Jul 18, 2021	DP		
	6627210*PED	Jan 18, 2022			
	6641834	Jul 28, 2021	DP		
	6641834*PED	Jan 28, 2022			
	6673337	Jul 26, 2021	DP		
	6673337*PED	Jan 26, 2022			
BROMFENAC SODIUM - XIBROM					
021664 001				I-485	Jan 27, 2009
BUDESONIDE - PULMICORT RESPULES					
020929 001	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
BUDESONIDE - PULMICORT RESPULES					
020929 002	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
BUDESONIDE - RHINOCORT					
020746 001	6986904	Apr 29, 2017	DP U-699		
BUDESONIDE - RHINOCORT					
020746 002	6986904	Apr 29, 2017	DP U-699		
CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)					
021823 001				M-52	Jan 24, 2009
CEFDITOREN PIVOXIL - SPECTRACEF					
021222 001	**>A>** 4839350	Apr 14, 2009	DS DP		
CETIRIZINE HYDROCHLORIDE - ZYRTEC					
019835 001	**>A>** 4525358	Jun 25, 2007	DS DP U-565		
	>A> 4525358*PED	Dec 25, 2007			
CETIRIZINE HYDROCHLORIDE - ZYRTEC					
019835 002	**>A>** 4525358	Jun 25, 2007	DS DP U-565		
	>A> 4525358*PED	Dec 25, 2007			
CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR					
021150 001	**>A>** 7014867	Jun 10, 2022	DP		
CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK					
021555 002	5690958	Sep 30, 2016	DP		
CICLOPIROX - LOPROX					
020519 001	7018656	Sep 05, 2018	DP		
	7026337	Apr 02, 2018	U-714		
CONIVAPTAN HYDROCHLORIDE - VAPRISOL					
021697 001	5723606	Mar 03, 2015	DS DP U-698		
DESFLURANE - SUPRANE					
020118 001	5617906	Apr 08, 2014	DP		
DESLORATADINE - CLARINEX					
021165 001	**>A>** 4659716	Mar 31, 2007	DP U-725		
	>A> 4659716	Mar 31, 2007	DP U-427		
	>A> 4659716*PED	Oct 01, 2007	U-427		
DESLORATADINE - CLARINEX					
021300 001	**>A>** 4659716	Mar 31, 2007	DP U-725		
	>A> 4659716	Mar 31, 2007	DP U-611		
	>A> 4659716*PED	Oct 01, 2007			
DESLORATADINE - CLARINEX					
021312 001	**>A>** 4659716	Mar 31, 2007	DP U-725		
	>A> 4659716	Mar 31, 2007	DP U-427		
	>A> 4659716*PED	Oct 01, 2007	U-427		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)		EXCLUSIVITY EXPIRATION DATE
DESLORATADINE - CLARINEX									
021312 002	**>A>**	4659716	Mar 31, 2007		DP	U-725			
	>A>	4659716	Mar 31, 2007		DP	U-427			
	>A>	4659716*PED	Oct 01, 2007		DP				
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR									
021605 001	**>A>**	4659716	Mar 31, 2007		DP	U-726			
	>A>	4659716	Mar 31, 2007		DP	U-644			
	>A>	4659716*PED	Oct 01, 2007						
		6979463	Mar 28, 2022		DP				
DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR									
021313 001	**>A>**	4659716	Mar 31, 2007		DP	U-707	NCE		Dec 21, 2006
	>A>	4659716*PED	Oct 01, 2007				NC		Mar 03, 2008
		6100274	Jul 07, 2019		DP		PED		Jun 21, 2007
		6100274*PED	Jan 07, 2010						
		6709676	Feb 18, 2021		DP	U-707			
DOCETAXEL - TAXOTERE									
020449 001		5750561	Jul 03, 2012		DP		I-490		Mar 22, 2009
DONEPEZIL HYDROCHLORIDE - ARICEPT ODT									
021720 001		4895841	Nov 25, 2010	DS	DP	U-713			
DONEPEZIL HYDROCHLORIDE - ARICEPT ODT									
021720 002		4895841	Nov 25, 2010	DS	DP	U-713			
DROSPIRENONE; ETHINYL ESTRADIOL - YAZ									
021676 001	**>A>**	5569652	Oct 29, 2013			U-1	NP		Mar 16, 2009
	>A>	5798338	Jul 10, 2015		DP				
	>A>	6787531	Aug 31, 2020		DP				
	>A>	6933395	Aug 11, 2017		DP				
	>A>	RE37564	Jun 30, 2014		DP				
	>A>	RE37838	Jun 30, 2014		DP				
	>A>	RE38253	Jun 30, 2014		DP				
EPLERENONE - INSPRA									
021437 001	**>A>**	4559332	Apr 09, 2007	DS	DP	U-537			
EPLERENONE - INSPRA									
021437 002	**>A>**	4559332	Apr 09, 2007	DS	DP	U-537			
EPLERENONE - INSPRA									
021437 003	**>A>**	4559332	Apr 09, 2007	DS	DP	U-537			
ESOMEPRAZOLE MAGNESIUM - NEXIUM									
021153 001	**>A>**	4738974	Apr 19, 2007	DS	DP	U-635	I-484		Nov 24, 2007
	>A>	4738974	Apr 19, 2007	DS	DP	U-373	**>A>** NPP		Apr 28, 2009
	>A>	4738974*PED	Oct 19, 2007			U-373			
ESOMEPRAZOLE MAGNESIUM - NEXIUM									
021153 002	**>A>**	4738974	Apr 19, 2007	DS	DP	U-635	I-484		Nov 24, 2007
	>A>	4738974	Apr 19, 2007	DS	DP	U-373	**>A>** NPP		Apr 28, 2009
	>A>	4738974*PED	Oct 19, 2007			U-373			
ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA									
021180 001		5876746	Nov 20, 2015		DP	U-514			
ETHINYL ESTRADIOL; NORETHINDRONE - OVCON-35									
021490 001	**>A>**	6667050	Apr 06, 2019		DP	U-1			
ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE									
021871 001		5552394	Jul 22, 2014			U-1	NP		Feb 17, 2009
FENOFIBRATE - FENOFIBRATE									
076433 001							PC		May 22, 2006
FENOFIBRATE - FENOFIBRATE									
076433 002							PC		May 22, 2006
FENOFIBRATE - LIPOFEN									
021612 001		5545628	Jan 10, 2015			U-701			
FENOFIBRATE - LIPOFEN									
021612 002		5545628	Jan 10, 2015			U-701			
FENOFIBRATE - LIPOFEN									
021612 003		5545628	Jan 10, 2015			U-701			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - TRICOR					
021656 001	**>A>** 7037529	Jan 09, 2018	DP		
	>A> 7041319	Jan 09, 2018	DP		
FENOFIBRATE - TRICOR					
021656 002	**>A>** 7037529	Jan 09, 2018	DP		
	>A> 7041319	Jan 09, 2018	DP		
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR					
021704 001	**>A>** RE39069	May 29, 2018	DP		
FLUNISOLIDE - AEROSPAN HFA					
021247 001				NP	Jan 27, 2009
FLUOCINOLONE ACETONIDE - RETISERT					
021737 001	6217895	Mar 22, 2019	DP U-708		
	6548078	Mar 22, 2019	DP U-708		
FLUOCINONIDE - VANOS					
021758 001				I-487	Mar 02, 2009
FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY					
021235 001	RE39030	May 29, 2017	DP U-397		
	RE39030	May 29, 2017	DP U-396		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 001	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 002	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 003	5658549	Sep 19, 2014	DP U-710	NPP	Feb 28, 2009
	5674472	Oct 07, 2014	DP		
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50					
021077 001	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50					
021077 002	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50					
021077 003	4992474	Feb 12, 2008	U-211		
	4992474*PED	Aug 12, 2008	U-211		
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008	U-211		
	5225445*PED	Aug 12, 2008	U-211		
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FROVATRIPTAN SUCCINATE - FROVA					
021006 001	5464864	Nov 07, 2015	U-436		
FULVESTRANT - FASLODEX					
021344 001	4659516	Oct 01, 2006			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLIMEPIRIDE - AMARYL					
020496 001				M-54	Nov 28, 2008
				PED	May 28, 2009
GLIMEPIRIDE - AMARYL					
020496 002				M-54	Nov 28, 2008
				PED	May 28, 2009
GLIMEPIRIDE - AMARYL					
020496 003				M-54	Nov 28, 2008
				PED	May 28, 2009
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL					
021700 001	5002953	Sep 17, 2011	DS DP U-690		
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP U-690		
	5741803*PED	Oct 21, 2015			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL					
021700 002	5002953	Sep 17, 2011	DS DP U-690		
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP U-690		
	5741803*PED	Oct 21, 2015			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL					
021700 003	5002953	Sep 17, 2011	DS DP U-690		
	5002953*PED	Mar 17, 2012			
	5741803	Apr 21, 2015	DS DP U-690		
	5741803*PED	Oct 21, 2015			
HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT					
021859 001				NCE	Dec 02, 2010
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT					
020818 004				>A> NS	Apr 28, 2009
HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT					
020818 005				>A> NS	Apr 28, 2009
IBANDRONATE SODIUM - BONIVA					
021455 001	4927814	Jul 09, 2007	DS DP U-642		
	6143326	Apr 21, 2017	U-642		
IBANDRONATE SODIUM - BONIVA					
021858 001	4927814	Jul 09, 2007	DS DP U-700	NDF	Jan 06, 2009
				NCE	May 16, 2008
IBUPROFEN LYSINE - NEOPROFEN					
021903 001				>A> NE	Apr 13, 2009
				>A> ODE	Apr 13, 2013
INSULIN DETEMIR RECOMBINANT - LEVEMIR					
021536 001				I-489	Oct 19, 2008
INSULIN RECOMBINANT HUMAN - EXUBERA					
021868 001	5740794	Apr 21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar 07, 2014	U-704		
	6051256	Mar 07, 2014	DP		
	6257233	May 14, 2019	U-704		
	6423344	Mar 07, 2014	DP		
	6543448	Sep 21, 2014	DP		
	6546929	May 14, 2019	U-704		
	6582728	Jun 24, 2020	DP		
	6592904	Mar 07, 2014	DP		
	6685967	Sep 11, 2018	DP		
	6737045	Mar 07, 2014	U-704		
	RE37872	Feb 12, 2010	DP		
	RE38385	Feb 12, 2010	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN RECOMBINANT HUMAN - EXUBERA							
021868 002	5740794	Apr 21, 2015		DP		NP	Jan 27, 2009
	5997848	Mar 07, 2014			U-704		
	6051256	Mar 07, 2014		DP			
	6257233	May 14, 2019			U-704		
	6423344	Mar 07, 2014		DP			
	6543448	Sep 21, 2014		DP			
	6546929	May 14, 2019			U-704		
	6582728	Jun 24, 2020		DP			
	6592904	Mar 07, 2014		DP			
	6685967	Sep 11, 2018		DP			
	6737045	Mar 07, 2014			U-704		
	RE37872	Feb 12, 2010		DP			
	RE38385	Feb 12, 2010		DP			
IPRATROPIUM BROMIDE - ATROVENT HFA							
021527 001	6983743	May 26, 2020		DP			
LANSOPRAZOLE - PREVACID							
020406 001	6749864	Feb 13, 2007		DP			
LANSOPRAZOLE - PREVACID							
020406 002	6749864	Feb 13, 2007		DP			
LANSOPRAZOLE - PREVACID							
021281 001	6749864	Feb 13, 2007		DP			
LANSOPRAZOLE - PREVACID							
021281 002	6749864	Feb 13, 2007		DP			
LANSOPRAZOLE - PREVACID							
021428 001	6749864	Feb 13, 2007		DP			
LANSOPRAZOLE - PREVACID							
021428 002	6749864	Feb 13, 2007		DP			
LANTHANUM CARBONATE - FOSRENOL							
021468 003	5968976	Mar 19, 2016		DP	U-613		
LANTHANUM CARBONATE - FOSRENOL							
021468 004	5968976	Mar 19, 2016		DP	U-613		
LENALIDOMIDE - REVLIMID							
021880 001	5635517	Jul 24, 2016	DS			ODE	Dec 27, 2012
	6045501	Aug 28, 2018			U-694		
	6315720	Oct 23, 2020			U-694		
	6555554	Jul 24, 2016		DP			
	6561976	Aug 28, 2018			U-694		
	6561977	Oct 23, 2020			U-694		
	6755784	Oct 23, 2020			U-694		
	6908432	Aug 28, 2018			U-694		
LENALIDOMIDE - REVLIMID							
021880 002	5635517	Jul 24, 2016	DS			ODE	Dec 27, 2012
	6045501	Aug 28, 2018			U-694		
	6315720	Oct 23, 2020			U-694		
	6555554	Jul 24, 2016		DP			
	6561976	Aug 28, 2018			U-694		
	6561977	Oct 23, 2020			U-694		
	6755784	Oct 23, 2020			U-694		
	6908432	Aug 28, 2018			U-694		
LEVETIRACETAM - KEPPRA							
021035 004						**>A>** NPP	Jun 21, 2008
LIDOCAINE; TETRACAINE - SYNERA							
021623 001						NC	Jun 23, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE	PATENT CODES			EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOPINAVIR; RITONAVIR - KALETRA								
021906 001		5541206	Jul 30, 2013	DS	DP	U-688		
		5541206*PED	Jan 30, 2014					
		5635523	Jun 03, 2014			U-688		
		5635523*PED	Dec 03, 2014					
		5648497	Jul 15, 2014	DS	DP			
		5648497*PED	Jan 15, 2015					
		5674882	Oct 07, 2014			U-688		
		5674882*PED	Apr 07, 2015					
		5846987	Dec 29, 2012			U-688		
		5846987*PED	Jun 29, 2013					
		5886036	Dec 29, 2012		DP			
		5886036*PED	Jun 29, 2013					
		6037157	Jun 26, 2016			U-688		
		6037157*PED	Dec 26, 2016					
		6703403	Jun 26, 2016			U-688		
		6703403*PED	Dec 26, 2016					
LOVASTATIN; NIACIN - ADVICOR								
021249 001		7011848	Sep 20, 2013			U-712		
LOVASTATIN; NIACIN - ADVICOR								
021249 002		7011848	Sep 20, 2013			U-712		
LOVASTATIN; NIACIN - ADVICOR								
021249 003		7011848	Sep 20, 2013			U-712		
LUBIPROSTONE - AMITIZA								
021908 001	**>A>**	5284858	Feb 08, 2011	DS	DP		NCE	Jan 31, 2011
	>A>	5317032	May 31, 2011	DS	DP	U-717		
	>A>	6414016	Sep 05, 2020	DS	DP	U-717		
	>A>	6583174	Oct 16, 2020	DS	DP			
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID								
021850 001	**>A>**	6645988	Jul 16, 2016	DS	DP	U-623		
	>A>	6645988	Jul 16, 2016	DS	DP	U-588		
MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID								
021850 002	**>A>**	6645988	Jul 16, 2016	DS	DP	U-623		
	>A>	6645988	Jul 16, 2016	DS	DP	U-588		
MECASERMIN RINFABATE RECOMBINANT - IPLEX								
021884 001		5200509	Apr 06, 2010	DS				
		5681818	Oct 28, 2014			U-697		
MELOXICAM - MOBIC								
020938 001							ODE	Aug 11, 2012
							PED	Feb 11, 2013
MELOXICAM - MOBIC								
020938 002							ODE	Aug 11, 2012
							PED	Feb 11, 2013
MELOXICAM - MOBIC								
021530 001							I-469	Aug 11, 2008
							ODE	Aug 11, 2012
							PED	Feb 11, 2013
							PED	Feb 11, 2009
MEQUINOL; TRETINOIN - SOLAGE								
020922 001	**>A>**	5194247	Dec 10, 2013		DP	U-294		
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION								
021026 001	**>A>**	4911932	Mar 27, 2007		DP	U-718	NP	Feb 16, 2009
MINOXIDIL - MEN'S ROGAINE								
021812 001		6946120	Apr 20, 2019		DP	U-702	NDF	Jan 20, 2009
MODAFINIL - PROVIGIL								
020717 001		4927855	May 22, 2007			U-255	I-449	Jan 23, 2007
		4927855*PED	Nov 22, 2007				ODE	Dec 24, 2005
		RE37516	Oct 06, 2014			U-255	PED	Jul 23, 2007
		RE37516*PED	Apr 06, 2015				PED	Jun 24, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MODAFINIL - PROVIGIL					
020717 002	4927855	May 22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov 22, 2007		ODE	Dec 24, 2005
	RE37516	Oct 06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr 06, 2015		PED	Jun 24, 2006
MORPHINE SULFATE - KADIAN					
020616 004	5378474	Mar 23, 2010			
MORPHINE SULFATE - KADIAN					
020616 005	5202128	Apr 13, 2010			
	5378474	Mar 23, 2010			
MOXIFLOXACIN HYDROCHLORIDE - AVELOX					
021085 001	4990517	Dec 08, 2011 DS	DP U-298		
	6610327	Oct 29, 2019	DP U-298		
MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER					
021277 001	4990517	Dec 08, 2011 DS	DP U-298		
	6548079	Jul 25, 2020	DP U-298		
MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX					
021598 001	4990517	Dec 08, 2011 DS	DP U-709		
	4990517*PED	Jun 08, 2012			
NALTREXONE - VIVITROL					
021897 001				**>A>** NDF	Apr 13, 2009
NELARABINE - ARRANON					
021877 001	5747472	Feb 20, 2013	U-696		
	5747472	Feb 20, 2013	U-695		
	5747472	Feb 20, 2013	U-689		
	5821236	Feb 20, 2013	U-695		
NIACIN - NIASPAN					
020381 001	7011848	Sep 20, 2013	U-712		
NIACIN - NIASPAN					
020381 002	7011848	Sep 20, 2013	U-712		
NIACIN - NIASPAN					
020381 003	7011848	Sep 20, 2013	U-712		
NIACIN - NIASPAN					
020381 004	7011848	Sep 20, 2013	U-712		
NIACIN - NIASPAN TITRATION STARTER PACK					
020381 005	7011848	Sep 20, 2013	U-712		
NICOTINE POLACRILEX - NICOTINE POLACRILEX					
077007 001				PC	Aug 21, 2006
NICOTINE POLACRILEX - NICOTINE POLACRILEX					
077007 002				PC	Aug 21, 2006
OCTREOTIDE ACETATE - SANDOSTATIN					
019667 001	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN					
019667 002	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN					
019667 003	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN					
019667 004	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			
OCTREOTIDE ACETATE - SANDOSTATIN					
019667 005	5753618	May 19, 2015			
	5753618*PED	Nov 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OCTREOTIDE ACETATE - SANDOSTATIN LAR					
021008 001	5538739	Jul 23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan 23, 2014		PED	May 25, 2006
	5639480	Jun 17, 2014			
	5639480*PED	Dec 17, 2014			
	5688530	Nov 18, 2014	U-268		
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016			
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016			
	5922682*PED	Jan 13, 2017			
OCTREOTIDE ACETATE - SANDOSTATIN LAR					
021008 002	5538739	Jul 23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan 23, 2014		PED	May 25, 2006
	5639480	Jun 17, 2014			
	5639480*PED	Dec 17, 2014			
	5688530	Nov 18, 2014	U-268		
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016			
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016			
	5922682*PED	Jan 13, 2017			
OCTREOTIDE ACETATE - SANDOSTATIN LAR					
021008 003	5538739	Jul 23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan 23, 2014		PED	May 25, 2006
	5639480	Jun 17, 2014			
	5639480*PED	Dec 17, 2014			
	5688530	Nov 18, 2014	U-268		
	5688530*PED	May 18, 2015			
	5922338	Jul 13, 2016			
	5922338*PED	Jan 13, 2017			
	5922682	Jul 13, 2016			
	5922682*PED	Jan 13, 2017			
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID					
021849 001	6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP		
	6699885	Jul 16, 2016		U-588	
OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID					
021849 002	**>A>** 6489346	Jul 16, 2016	DS DP	U-623	
	>A> 6489346	Jul 16, 2016	DS DP	U-588	
	6645988	Jul 16, 2016	DS DP		
	>A> 6699885	Jul 16, 2016		U-623	
	>A> 6699885	Jul 16, 2016		U-588	
OXALIPLATIN - ELOXATIN					
021492 001	5420319	Aug 09, 2016	DS		
OXALIPLATIN - ELOXATIN					
021492 002	5420319	Aug 09, 2016	DS		
OXALIPLATIN - ELOXATIN					
021759 001	5420319	Aug 08, 2016	DS		
OXALIPLATIN - ELOXATIN					
021759 002	5420319	Aug 08, 2016	DS		
OXCARBAZEPINE - TRILEPTAL					
021014 001	**>A>** 7037525	Feb 12, 2018		U-724	
OXCARBAZEPINE - TRILEPTAL					
021014 002	**>A>** 7037525	Feb 12, 2018		U-724	
OXCARBAZEPINE - TRILEPTAL					
021014 003	**>A>** 7037525	Feb 12, 2018		U-724	
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX					
020667 001	4843086	Jun 27, 2006		U-231	
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX					
020667 002	4843086	Jun 27, 2006		U-231	
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX					
020667 003	4843086	Jun 27, 2006		U-231	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 004		4843086	Jun 27, 2006			U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 005		4843086	Jun 27, 2006			U-231		
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX								
020667 006		4843086	Jun 27, 2006			U-231		
PRAVASTATIN SODIUM - PRAVASTATIN SODIUM								
076056 001							**>A>** PC	Oct 21, 2006
PRAVASTATIN SODIUM - PRAVASTATIN SODIUM								
076056 002							**>A>** PC	Oct 21, 2006
PRAVASTATIN SODIUM - PRAVASTATIN SODIUM								
076056 003							**>A>** PC	Oct 21, 2006
QUETIAPINE FUMARATE - SEROQUEL								
020639 006		4879288	Sep 26, 2011	DS	DP	U-550		
QUETIAPINE FUMARATE - SEROQUEL								
020639 007		4879288	Sep 26, 2011	DS	DP	U-550		
RALOXIFENE HYDROCHLORIDE - EVISTA								
020815 001		RE38968	Jul 28, 2012			U-662		
		RE38968	Jul 28, 2012			U-657		
		RE39049	Jul 28, 2012			U-662		
		RE39049	Jul 28, 2012			U-657		
		RE39050	Mar 02, 2014			U-662		
		RE39050	Mar 02, 2014			U-657		
RANOLAZINE - RANEXA								
021526 002		4567264	May 18, 2006	DS			NCE	Jan 27, 2011
		6303607	May 27, 2019			U-705		
		6369062	May 27, 2019		DP			
		6479496	May 27, 2019			U-705		
		6503911	May 27, 2019		DP			
		6525057	May 27, 2019			U-705		
		6562826	May 27, 2019			U-705		
		6617328	May 27, 2019		DP			
		6620814	May 27, 2019			U-705		
		6852724	May 27, 2019			U-705		
		6864258	May 27, 2019			U-705		
RISEDRONATE SODIUM - ACTONEL								
020835 001							M-52	Jan 24, 2009
RISEDRONATE SODIUM - ACTONEL								
020835 002							M-52	Jan 24, 2009
RISEDRONATE SODIUM - ACTONEL								
020835 003							M-52	Jan 24, 2009
ROCURONIUM BROMIDE - ZEMURON (P/F)								
020214 003	**>A>**	4894369	Apr 13, 2008					
SALMETEROL XINAFOATE - SEREVENT								
020236 001		4992474	Feb 12, 2008					
		4992474*PED	Aug 12, 2008					
		5126375	Feb 12, 2008					
		5126375*PED	Aug 12, 2008					
		5225445	Feb 12, 2008			U-182		
		5225445*PED	Aug 12, 2008					
SALMETEROL XINAFOATE - SEREVENT								
020692 001		4992474	Feb 12, 2008					
		4992474*PED	Aug 12, 2008					
		5126375	Feb 12, 2008					
		5126375*PED	Aug 12, 2008					
		5225445	Feb 12, 2008			U-211		
		5225445*PED	Aug 12, 2008					
SELEGILINE - EMSAM								
021336 001		RE34579	Aug 18, 2007	DS	DP	U-711	NDF	Feb 27, 2009
SELEGILINE - EMSAM								
021336 002		RE34579	Aug 18, 2007	DS	DP	U-711	NDF	Feb 27, 2009

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO		PATENT NO	PATENT EXPIRATON DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SELEGILINE - EMSAM								
021336 003		RE34579	Aug 18, 2007	DS	DP	U-711	NDF	Feb 27, 2009
SEVELAMER HYDROCHLORIDE - RENAGEL								
021179 001		7014846	Aug 11, 2013		DP	U-246		
SEVELAMER HYDROCHLORIDE - RENAGEL								
021179 002		7014846	Aug 11, 2013		DP	U-246		
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP								
021892 001	**>A>**	5616346	May 18, 2013		DP	U-715	NP	Mar 16, 2009
SORAFENIB TOSYLATE - NEXAVAR								
021923 001							ODE	Dec 20, 2012
SUNITINIB MALATE - SUTENT								
021938 001		6573293	Feb 15, 2021	DS	DP	U-703	NCE	Jan 26, 2011
SUNITINIB MALATE - SUTENT								
021938 002		6573293	Feb 15, 2021	DS	DP	U-703	NCE	Jan 26, 2011
SUNITINIB MALATE - SUTENT								
021938 003		6573293	Feb 15, 2021	DS	DP	U-703	NCE	Jan 26, 2011
TACROLIMUS - PROGRAF								
050708 001							ODE	Mar 29, 2013
TACROLIMUS - PROGRAF								
050708 002							ODE	Mar 29, 2013
TACROLIMUS - PROGRAF								
050708 003							ODE	Mar 29, 2013
TACROLIMUS - PROGRAF								
050709 001							ODE	Mar 29, 2013
TERIPARATIDE RECOMBINANT HUMAN - FORTEO								
021318 001		6977077	Aug 19, 2019			U-597		
THYROTROPIN ALFA - THYROGEN								
020898 001							M-53	Jan 23, 2009
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA								
021395 001	**>A>**	RE38912	Oct 11, 2021		DP			
TOPIRAMATE - TOPAMAX								
020505 001	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX								
020505 002	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX								
020505 003	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX								
020505 004	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX								
020505 005	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX								
020505 006	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX SPRINKLE								
020844 001	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX SPRINKLE								
020844 002	**>A>**	7018983	Oct 13, 2015			U-723		
TOPIRAMATE - TOPAMAX SPRINKLE								
020844 003	**>A>**	7018983	Oct 13, 2015			U-723		
TREPROSTINIL SODIUM - REMODULIN								
021272 001		5153222	Oct 06, 2014			U-455		
TREPROSTINIL SODIUM - REMODULIN								
021272 002		5153222	Oct 06, 2014			U-455		
TREPROSTINIL SODIUM - REMODULIN								
021272 003		5153222	Oct 06, 2014			U-455		
TREPROSTINIL SODIUM - REMODULIN								
021272 004		5153222	Oct 06, 2014			U-455		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANAMIVIR - RELENZA						
021036 001	**>A>** 5648379	Jul 15, 2014		U-722	I-491	Mar 29, 2009
	>A> 5648379	Jul 15, 2014		U-721		
	>A> 5648379	Jul 15, 2014		U-274		
	>A> 6294572	Dec 15, 2014	DS	DP		
ZIPRASIDONE HYDROCHLORIDE - GEODON						
021483 001	**>A>** 4831031	Mar 02, 2007	DS	DP U-720		
	>A> 5312925	Sep 01, 2012	DS	DP U-720		
	>A> 6150366	May 27, 2019		DP U-719		
	>A> 6245766	Dec 18, 2018		U-601		
ZOLEDRONIC ACID - ZOMETA						
021223 001	4939130	Sep 02, 2012	DS	DP U-53		
ZOLEDRONIC ACID - ZOMETA						
021223 002	4939130	Sep 02, 2012	DS	DP U-53		

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:
   DS = Drug Substance claim
   DP = Drug Product claim
   U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at http://www.fda.gov/cder/orange/patex.htm
3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm